Compounds and methods for preventing influenza virus transmission - Patents.com

JP7579269B2Active Publication Date: 2024-11-07F HOFFMANN LA ROCHE & CO AG +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021557775
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-03-29
Filing Date
2020-03-26
Publication Date
2024-11-07
Estimated Expiration
2040-03-26

AI Technical Summary

Benefits of technology

【0013】 さらに、鼻/喉でのウイルス排出と伝播との間に絶対的な相関関係はない。ヒトにおいて、例えばH5N1ウイルスは感染した患者では非常に高い力価に達するが、空気中や人と人の間では伝播しない。フェレットモデルでは、伝播性のタイトなウィンドウを示したがウイルス排出のピークのタイミングと必ずしも相関しなかった(Roberts, PLoS One 7.8 (2012):e43303)。さらに、本発明者らにより電線が臨床症状と相関しないことが示されたため、症状の減少によって伝播の減少が明らかになるわけではない。実際、インフルエンザは、多くは無症状か発症前に伝播するというコンセンサスがある(Fraser、Proceedings of the National Academy of Sciences 101.16(2004):6146-6151)。したがって、既知の薬剤がインフルエンザの処置に有効であるという事実は全くもって、この薬剤がインフルエンザウイルスの伝播の減少にも有効であることを示すものではない。しかしながら、本発明の文脈において、驚くべきことに、バロキサビルマルボキシルがインフルエンザウイルスの伝播を有意に減少させることが見出された。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579269000008
    Figure 0007579269000008
  • Figure 0007579269000009
    Figure 0007579269000009
  • Figure 0007579269000010
    Figure 0007579269000010
Patent Text Reader

Abstract

The present invention relates to a method for preventing the transmission of influenza virus, comprising administering to a patient infected with influenza virus (referred to herein as an "index patient") an effective amount of a compound having formula (I) or (II) or a pharmaceutically acceptable salt thereof. The compound used in the present invention reduces the infectivity of influenza virus in index patients, and therefore reduces the risk of index patients causing an influenza epidemic or influenza pandemic compared to control patients. Accordingly, one aspect of the present invention relates to a method for preventing an influenza epidemic or influenza pandemic, comprising administering to patients infected with influenza virus (index patients) an effective amount of a compound having formula (I) or (II) or a pharmaceutically acceptable salt thereof, to at least 10% of all influenza-infected individuals in a city or country's population.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for preventing the transmission of influenza virus, comprising administering to a patient infected with influenza virus (hereinafter referred to as "index patient") an effective amount of a compound having formula (I) or (II) or a pharma- ceutically acceptable salt thereof. The compound used in the present invention reduces the infectivity of influenza virus in index patients, and thus reduces the risk of index patients causing an influenza epidemic or influenza pandemic, compared to control patients. Thus, one aspect of the present invention relates to a method for preventing an influenza epidemic or influenza pandemic, comprising administering to a patient infected with influenza virus (index patient) an effective amount of a compound having formula (I) or (II) or a pharma- ceutically acceptable salt thereof, to at least 10% of all influenza-infected people in a city or country's population. [Background technology]

[0002] Influenza virus disease is an acute respiratory infection caused by influenza viruses and spreads mainly through the air, especially droplets. Influenza A and B viruses are highly transmissible (Vanderlinden, Med Res Rev 2014;34(2):301-339). Thus, influenza epidemics often arise from seasonal influenza viruses and impose a large burden on human health on a global scale. There are an estimated 3 to 5 million severe cases worldwide, and approximately 290,000 to 650,000 people die from influenza every year (WHO News Release, Geneva, Switzerland, 14 December 2017;WHO Fact Sheet, Geneva, Switzerland, 31 January 2018;Baxter D, Hum Vaccin Immunother. 2016;12(10):2712-2717). Influenza also impacts society through increased demand for health services each season and reduced workforce productivity (WHO Fact Sheet, Geneva, Switzerland, 31 January 2018).

[0003] Influenza epidemics are sudden and unavoidable events even today. Several influenza pandemics have caused global health emergencies in the past century. The first and most severe is estimated to have caused more than 40 to 50 million deaths worldwide (Francis, Am J Hyg., 1945, 42:1-11). Experts expect the next pandemic to be associated with high mortality and severe illness requiring hospitalization, placing a considerable strain on health resources. Pandemics are global in nature, and few countries are spared. The impact can be devastating in developing countries, where health resources are already scarce and the general population is often debilitated by poor health and nutrition.

[0004] The circumstances surrounding the 1997 “bird flu” outbreak in Hong Kong highlight the need for advance planning to ensure an appropriate response to health emergencies that are unpredictable, complex, rapidly evolving, and certain to involve great public anxiety. In the past, once a pandemic began, it was too late to accomplish many of the key activities necessary to minimize the impact. Thus, planning and implementation of preparedness activities must begin well in advance. Planning for pandemics also enhances the ability to respond to other large-scale health emergencies, including bioterrorism threats, which require significant preventive and treatment interventions and strong national plans with risk communication components to help calm public fears. The impacts of pandemic influenza can be orders of magnitude greater than a typical bioterrorism scenario. Unlike most other health emergencies, pandemics occur in several waves and last for 1-2 years. Thus, response efforts need to be sustained for a long period of time. Moreover, preparing for influenza pandemics enhances the response to influenza epidemics, which occur annually and are thought to kill between 500,000 and 1 million people annually worldwide. Thus, investments in pandemic preparedness have direct and immediate utility as a means to reduce the impact of certain recurring events.

[0005] Annual vaccination programs are the cornerstone of efforts to prevent influenza infection, but the effectiveness of these programs varies due to suboptimal postvaccination uptake and mismatch between the vaccine and circulating influenza strains (Centers for Disease Control and Prevention “Vaccine effectiveness - how well does the flu vaccine work?” 3rd October 2017). M2 inhibitors, such as amantadine, and neuraminidase inhibitors, such as oseltamivir, are typical drugs used against influenza. However, modeling studies of M2 inhibitor use in institutional outbreak settings have shown that treatment alone does not significantly affect the course of the outbreak, and treatment with these anti-influenza drugs does not reduce the likelihood of transmission (Stilianakis, Journal of Infectious Diseases, 1998, 177:863-873). Currently, no drugs have been proven to reduce influenza transmission. Therefore, finding antiviral drugs that reduce influenza virus transmission and thereby prevent or mitigate the occurrence of seasonal influenza epidemics or influenza pandemics is an important unmet medical need. Summary of the Invention [Problem to be solved by the invention]

[0006] Therefore, the technical problem underlying the present invention is the provision of means and methods for protecting the health of society. [Means for solving the problem]

[0007] The technical problem is solved by providing the embodiments characterized in the claims.

[0008] Thus, the present invention provides compounds of formula I or II: [ka] or a pharma- ceutically acceptable salt thereof to a patient (initial patient) infected with influenza virus.

[0009] Thus, the present invention relates to a compound for use in treating influenza virus infection in a patient (initial case patient), the compound having formula (I) or (II) or a pharma- ceutically acceptable salt thereof, which prevents (e.g., reduces) the transmission of influenza virus. The present invention also includes a pharmaceutical composition comprising a compound having formula (I) or (II), or a pharma- ceutically acceptable salt thereof, and optionally a pharma- ceutically acceptable carrier, which prevents (e.g., reduces) the transmission of influenza virus. The pharmaceutical composition is particularly useful for treating a patient (initial case patient) infected with influenza, which prevents (e.g., reduces) the transmission of influenza virus in the patient.

[0010] As shown in the accompanying examples, the compounds used in the present invention have the advantageous effect of reducing transmission. Thus, the compounds reduce the likelihood of an influenza epidemic or pandemic occurring or reduce the spread of an existing influenza epidemic or pandemic. The compounds used in the present invention are also valuable tools for weakening the impact of influenza virus bioterrorism attacks, such as the spread of pandemic influenza viruses. Thus, the compounds are particularly useful for treating certain types of influenza virus infections, i.e., infections caused by influenza virus strains with epidemic or pandemic potential. The unexpected technical effect of the compounds used in the present invention to reduce influenza virus transmission clearly leads to new clinical situations. Indeed, with this advantageous technical effect in mind, the attending physician will treat with the compounds in particular patients whose infectiousness could cause damage (e.g., economic or social) if it is not reduced. Such patients are, for example, patients who are in personal contact with members of groups at risk for influenza (such as those at high risk of infection with influenza viruses) or patients at high risk of developing severe influenza-related complications (such as the elderly, young children, severely ill or immunocompromised individuals). For example, treatment with the compounds used in the present invention is very beneficial for influenza patients who stay at home during the infection period and have the opportunity to come into contact with family members (e.g., young children) during that time. Furthermore, due to their advantageous properties of reducing influenza transmission, the compounds of the present invention can be used to treat people who are essential for society to function, allowing these people to continue working while infected with influenza virus without infecting their colleagues or other contacts. For example, the compounds used in the present invention can be advantageously used to treat medical workers, especially at the beginning stage of an influenza epidemic or pandemic. The compounds can also be used to treat patients who come into contact with many people while they are infected with influenza virus (e.g., because they have to fly by plane). Indeed, several times in the past, it has been necessary to quarantine airplanes due to sudden outbreaks of illness, especially during long-distance flights.Thus, the means and methods described herein advantageously reduce the social and economic impacts associated with influenza virus infection.

[0011] It has been shown that the effect of a drug in reducing transmission cannot be concluded from its effectiveness against influenza (e.g., the effectiveness of the drug in reducing influenza symptoms, viral load, viral shedding, or viral RNA). In fact, the accompanying examples show that oseltamivir, a commonly known and effective anti-influenza drug, does not prevent influenza virus transmission at all. The accompanying examples also show that the viral RNA present in the nasal washes of influenza-infected subjects is identical to that of subjects treated with the compounds of the present invention (especially baloxavir marboxil), oseltamivir, or placebo (see, e.g., Figures 6, 9, and 12). However, for unknown reasons, viral transmission was significantly reduced in subjects treated with baloxavir compared to subjects treated with oseltamivir or placebo.

[0012] The fact that an anti-influenza drug reduces influenza symptoms does not necessarily indicate that this drug is also suitable for reducing influenza virus transmission. Since influenza symptoms may remain after the virus, viral load, and viral shedding have been resolved, the effect of reducing transmission cannot be predicted without well-organized non-clinical experiments mimicking a human model. Transmission (e.g. within a household) is influenced by many factors. Therefore, the fact that a drug reduces viral shedding or viral load does not directly allow us to conclude that this drug also reduces transmission.

[0013] Furthermore, there is no absolute correlation between viral shedding in the nose / throat and transmission. In humans, for example, the H5N1 virus reaches very high titers in infected patients, but is not transmitted through the air or between people. Ferret models showed a tight window of transmissibility that did not necessarily correlate with the timing of peak viral shedding (Roberts, PLoS One 7.8 (2012):e43303). Furthermore, reduced symptoms do not necessarily equate to reduced transmission, as we have shown that shedding does not correlate with clinical symptoms. Indeed, there is consensus that influenza is largely transmitted asymptomatically or presymptomatically (Fraser, Proceedings of the National Academy of Sciences 101.16(2004):6146-6151). Thus, the fact that a known drug is effective in treating influenza does not at all indicate that this drug is also effective in reducing influenza virus transmission. However, in the context of the present invention, it has surprisingly been found that baloxavir marboxil significantly reduces influenza virus transmission. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] As mentioned above, the present invention relates to the treatment of influenza patients whose infectivity should be prevented or reduced. In fact, according to the present invention, the term "prevent transmission" includes that the compound "reduces transmission" compared to a control patient who is not administered the compound used in the present invention. In this specification, the influenza patient whose infectivity should be prevented or reduced is referred to as "index patient" (or "patient zero"). This patient, which is further defined below, is anyone who is infected with influenza virus and whose infectivity needs to be prevented or reduced for any reason.

[0015] The compound used in the present invention reduces the infectivity of the influenza virus of the index patient. In this specification, the term "infectivity" refers to the ability of a pathogen, such as influenza virus, to establish infection in another host. In this specification, the terms "infectivity" and "transmissibility" have the same meaning and are defined as the frequency of the spread of a pathogen between hosts, including hosts in a parent-child relationship and hosts in a non-parent-child relationship. Therefore, according to the present invention, the compound reduces the ability of the influenza virus of the treated index patient to establish infection in another host. Or, in other words, the compound used in the present invention reduces the frequency of the influenza virus of the index patient to infect other hosts.

[0016] The accompanying examples surprisingly show that the transmission of influenza virus can be reduced immediately after administration of the compound used in the present invention. Moreover, the accompanying examples demonstrate that the infectivity of the treated index patient is further reduced within 24 hours after administration of the compound. Thus, in the context of the present invention, it is preferred that the index patient does not have personal contact with other people (i.e., contacts) until 1 hour, or 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, 30 hours, or 32 hours after administration of the compound used in the present invention. The periods described herein refer to minimum periods. For example, a period of "2 hours after administration" also includes longer periods such as 2.5 hours after administration. In fact, the present invention encompasses that the index patient does not have personal contact with people until 1 or 2 days (or 1 day and 1 or 2 nights) after administration of the compound used in the present invention. For example, the index patient may remain isolated in the hospital for a day (or a day and a night or two) so that personal contact with others is prevented during this period.

[0017] Consistent with this, in one aspect of the present invention, the transmission rate of influenza virus from index patients is reduced within 1 hour to 24 hours from the first administration of the compound. The infection rate of influenza virus from index patients can also be reduced within 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, 30 hours, or 32 hours from the first administration of the compound. Thus, the period can be extended. Thus, according to the present invention, the transmission rate of influenza virus from index patients is reduced within 1 hour to 32 hours (e.g., within 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, 30 hours, or 32 hours) from the first administration of the compound.

[0018] Thus, the compounds used in the present invention reduce the transmission rate of influenza virus from a treated index patient to a contact of the treated index patient, and can reduce the transmission rate of influenza virus from an index patient to 70% or less, preferably 50% or less, more preferably 30% or less, compared to the transmission rate of influenza virus from a control patient.

[0019] As used herein, the "transmission rate" corresponds to the percentage of infected individuals among contacts of an influenza-infected patient (i.e., index patient or control patient, respectively) within a specific time period. Thus, the "transmission rate" is the number of new cases (of infections by influenza virus strains originating from index patient or control patient, respectively) within a specific time period divided by the population at risk. The "population at risk" is preferably the number of people who have personal contact with the index patient or control patient, respectively, during influenza virus infection. Influenza virus can usually be transmitted from one day before influenza symptoms appear until influenza symptoms persist and recovery from the disease. Thus, the "population at risk" can be the number of people who have personal contact with the index patient or control patient, respectively, from one day before influenza symptoms appear until influenza symptoms persist. Preferably, the "population at risk" does not include people who have received influenza vaccination. As described herein above and below, the "transmission rate" is decreased after administration of the compound used in the present invention. Thus, the effect of the compound on the transmission rate is measured after administration of the compound. In particular, for the purpose of assessing the effect of the compound on the rate of transmission, the "at risk population" can be defined as the number of people (e.g., people who have not been vaccinated against influenza) who have had personal contact with the index patient during the period from the start of administration of the compound to the end of influenza symptoms. In line with this, the "at risk population" for a control patient can be defined as the number of people (e.g., people who have not been vaccinated against influenza) who have had personal contact with the control patient during the period from the start of administration of an anti-influenza drug other than the compound, or from a corresponding time point considering the influenza disease process if no anti-influenza drug is administered, to the end of influenza symptoms and recovery.

[0020] As described above, according to the present invention, the compound reduces the transmission rate of influenza virus in index patients (i.e., the infectivity of index patients) by 70% or less, preferably 50% or less, more preferably 30% or less, compared to the transmission rate of influenza virus in control patients not treated with the compound (i.e., compared to the infectivity of control patients not treated with the compound). In seasonal influenza, including influenza epidemics, influenza virus is transmitted from one patient to about 1.35 people in 5 days. Thus, when an index patient is infected with an influenza strain of seasonal influenza (including epidemic influenza strains, but not including pandemic influenza strains), the compound reduces the number of people to which the virus is transmitted to an average of about 0.945 people in 5 days (i.e., 70% transmission rate or less), preferably about 0.675 people in 5 days (i.e., 50% transmission rate or less), more preferably about 0.405 people in 5 days (i.e., 30% transmission rate or less). In pandemic influenza, influenza virus is transmitted from one patient to approximately 2.9 subjects over a 6-day period. Thus, if an index patient is infected with a pandemic influenza strain, the compounds reduce the number of people to which the virus will be transmitted to an average of approximately 2.03 or less people over a 6-day period (i.e., a 70% transmission rate), an average of approximately 1.45 or less people over a 6-day period (i.e., a 50% transmission rate), and more preferably, an average of approximately 0.87 or less people over a 6-day period (i.e., a 30% transmission rate).

[0021] Most people infected with influenza, which puts other housemates at risk of infection, are advised to stay home until they have been fever-free for at least 24 hours (Centers for Disease Control and Prevention. The flu:what to do if you get sick. 9th March 2018). If one housemate is infected with influenza, the transmission rate to cohabiting contacts can be up to 38%, with onset of symptoms delayed by about 3 days from the onset of symptoms in the index patient (Tsang, Trends Microbiol 2016;24(2):123-133). As described above, the compounds used in the present invention reduced the transmission rate of influenza virus from treated index patients to 70% or less, preferably 50% or less, and more preferably 30% or less. Thus, by treating index patients with the compounds, the risk of influenza virus transmission to cohabiting contacts is reduced to about 27% or less (i.e. 70%), preferably about 19% or less (i.e. 50%), and more preferably about 11.4% or less (i.e. 30%). This is of great advantage in preventing influenza epidemics or pandemics.

[0022] The attached examples show that the compound used in the present invention reduces the amount of virus released in the upper respiratory tract.According to the present invention, the compound reduces the amount of virus released in the upper respiratory tract of a new patient, compared with the amount of virus released in the upper respiratory tract of a control patient infected with influenza virus but not administered the compound.

[0023] The control patient may be any patient infected with influenza virus but not treated with the compound used in the present invention. Thus, according to the present invention, the control patient is infected with influenza virus but is not administered the compound. However, the control patient may be administered an anti-influenza drug other than the compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof. For example, the control patient may be administered oseltamivir. Thus, in one embodiment of the present invention, the control patient is administered any anti-influenza drug other than the compound of formula (I) or (II) or a pharmaceutically acceptable salt thereof. For example, the control patient may be administered oseltamivir. In another embodiment of the present invention, the control patient is not administered an anti-influenza drug, for example, is not administered oseltamivir. Oseltamivir can be administered at a dose of 75 mg twice a day for 5 days. The dose of oseltamivir in humans is generally known in the art. For example, for adults and adolescents (13 years or older), 75 mg is usually administered twice a day for 5 days. Dosing for pediatric patients aged 1-12 years is based on body weight and is typically given twice daily for 5 days. For infants aged 2 weeks to less than 1 year, the usual dose is 3 mg / kg twice daily for 5 days. The control patient has the same influenza virus strain as the index patient to which the control patient is compared. For example, if the index patient has a pandemic influenza virus strain, the control patient to which the index patient is compared has the same pandemic influenza virus strain.

[0024] A person skilled in the art is in a position to easily recognize whether transmission of influenza virus from a (treated) index patient or a control patient has occurred. For example, transmission occurs when at least one contact of the treated index patient or control patient is infected with influenza virus after personal contact with the treated index patient or control patient, respectively. The contact of the treated index patient is preferably (i) the patient is not infected with influenza virus at the time the compound is first administered to the index patient; and (ii) had personal contact with the index patient who was treated while the index patient was infected with influenza virus; is a human being.

[0025] With respect to item (ii) above, personal contact with the index patient is preferred within 10 days of administering the compound to the index patient. Thus, with respect to item (ii) above, it is preferred that the contactor has personal contact with the treated index patient within the period from the start of administration of the compound to 5 to 10 days (e.g., 9 days or 5 days) after administration of the compound.

[0026] Contacts of control patients are preferably: (i) not infected with influenza virus at the time the influenza antimicrobial agent was first administered to the control patient or, if the control patient was not administered the influenza antimicrobial agent, at a corresponding time point taking into account the influenza disease process; and (ii) had personal contact with the control patient during the period when the control patient was infected with influenza virus; is a person.

[0027] With respect to (ii) above, it is preferred that the contact has personal contact with the control patient within 10 days of administration of the anti-influenza drug to the control patient, or during a corresponding period of time in consideration of the influenza disease process if the control patient was not administered the anti-influenza drug. Thus, with respect to (ii) above, it is preferred that the contact has personal contact with the control patient within a period of time from the start of administration of the anti-influenza drug to the control patient, or from a corresponding time in consideration of the influenza disease process if the control patient was not administered the anti-influenza drug, to 5 to 10 days (e.g., 9 days or 5 days) after administration of the anti-influenza drug, or during a corresponding time in consideration of the influenza disease process if the control patient was not administered the anti-influenza drug.

[0028] Of course, a contact need not be in contact with the index case or control case, respectively, every day during the 10-day period. Rather, a contact may, for example, be in personal contact with the index case or control case, respectively, only one day out of the 10 days. For example, a contact may be in personal contact with the index case or control case, respectively, on about 7 days out of 9 days (e.g., due to a shared household).

[0029] In this specification, when counting the number of days after administration of the compound to the index patient or the other anti-influenza drug to the control patient, the day of administration is "day 0". Thus, day 1 (i.e., one day after administration of the compound or other anti-influenza drug, respectively) is the day after the administration day. Thus, 10 days after administration of the compound or other anti-influenza drug, respectively, refers to the day that is about 240 hours after administration of the compound or other anti-influenza drug, respectively.

[0030] As mentioned above, according to the present invention, a contact of a treated index or control patient is a person who: (i) for the index patient: the index patient was not infected with influenza virus at the time the compound was first administered to the index patient; or For control patients: not infected with influenza virus at the time when the influenza anti-influenza drug was first administered to the control patient or at the corresponding time when considering the influenza disease process if the influenza anti-influenza drug was not administered to the control patient; and (ii) With respect to the index patient: had personal contact with the index patient who was treated during the index patient's influenza virus infection period; or Regarding control patients: Had personal contact with the control patient during the control patient's influenza virus infection period.

[0031] According to the present invention, absence of influenza virus infection preferably means PCR negative for influenza virus (e.g. in a nasopharyngeal swab), and therefore preferably the contact was PCR negative for influenza at the time defined in (i) above.

[0032] PCR detection and quantification of influenza virus is commonly known in the art. For example, real-time reverse transcription PCR (RT-PCR) amplification of influenza matrix genes is used as a method to determine the presence or absence or amount of influenza RNA. RNA extraction and purification of influenza virus is a routine technique and can be performed, for example, using a MagNA Pure LC 1.0 or 2.0 isolation station (Roche Applied Science, product number 05197686001). To perform the test, nucleic acid is extracted from an aliquot of the swab specimen using the MagNA PureLC isolation station and MagNAPure LC Nucleic Acid Extraction Kit according to the manufacturer's instructions (Roche Applied Science). Reverse transcription and amplification reactions can be set up using Taqman Fast VirusMastermix. In clinical analysis, influenza A and B standard curves of four points (low, medium, high) of known virus particles / ml can be used as controls and are used in all runs. A universal internal control, Phocine Distemper Virus (PDV), can be added to each isolation to monitor the entire process from isolation to real-time detection. Additionally, a No Amplification Control (NAC) can be included in every PCR mix created to monitor contamination in every isolation. The positive control should give a positive signal that is present within the specified action limit. If the value of the positive control is outside the action limit, all samples tested with the same PCR mix should be retested. If the negative control shows a positive signal for influenza, all samples run with the same PCR mix should be retested. The output of the influenza RT-PCR assay is what is called the cycle threshold or Ct value, and the Ct value is recorded for each test. The Ct value is converted to a quantitative viral particles / ml value using a standard curve created simultaneously with the samples.

[0033] For influenza A positive subjects, influenza A subtype PCR assays can also be performed. More specifically, for influenza A positive subjects, real-time RT-PCR assays can be used to perform subtyping directly from the subject's swab sample. RNA can be isolated from clinical isolates as described above using the Roche MagNA Pure Total Nucleic Acid kit and amplified by one-step RT-PCR using influenza A subtype-specific primers. Further methods for detecting specific influenza virus subtypes, including suitable primer sequences, are generally known in the art and are described, for example, in "WHO information of the molecular detection of influenza viruses" of July 2017.

[0034] Those skilled in the art can easily determine the time points during influenza virus infection that correspond to a given influenza symptom (i.e., correspond to a given state in the influenza disease process). More specifically, it is generally known in the art that the influenza disease process can be monitored. For example, the influenza disease process can be monitored by monitoring clinical symptoms and / or virological measurements. Clinical symptoms can be monitored by: (i) Determine cough and nasal symptom scores (items 14 and 15 of the Canadian Acute Respiratory Illness and Flu Scale (CARIFS)). (ii) Ask the patient or their caregiver whether the patient has been able to return to daycare / school / work (if they have been able to do so at any time) or resume normal daily activities as they did before they developed influenza virus infection; and / or (iii) If the patient has already returned to normothermia (and preferably has remained so for at least 21.5 hours), determine the time when the patient first returns to normothermia (i.e., tympanic temperature below 37.2°C).

[0035] CARIFS is commonly known in the art and is shown in FIG.

[0036] Virological measurements can be monitored, for example, by measuring viral titer or viral shedding.

[0037] According to the invention, the personal contact between the contact and the index or control patient, respectively, is a personal contact that allows the transmission of influenza virus. For example, the personal contact can be a contact that allows airborne and / or direct contact transmission, preferably only airborne transmission. Contact transmission means direct virus transmission from an infected person to a susceptible person, e.g. via contaminated hands (direct contact transmission) or indirect virus transmission via objects (venom, indirect contact transmission). Transmission of the virus via the air (i.e. airborne transmission) can occur via droplets or aerosols. The generally accepted cut-off size between large droplets and small aerosols is 5 μm (Kutter, Current opinion in virology, 28 (2018):142-151). Droplets generated during coughing, sneezing, and talking do not remain suspended in the air. They usually remain in the air for less than 17 minutes, traveling less than 1 m before settling on the mucous membrane or surrounding surfaces of nearby contact objects (i.e. people in personal contact with the infected patient). Aerosols have a slow settling rate and can remain suspended in the air for distances greater than 1 m (Kutter, Current opinion in virology, 28 (2018):142-151). Studies to analyze the transmissibility of influenza viruses have shown that influenza virus RNA can be detected in the air up to 3.7 m away from patients, with the majority of the viral RNA contained in aerosols (<5 μm) (Kutter, Current opinion in virology, 28 (2018):142-151).

[0038] Thus, according to the present invention, personal contacts that allow transmission by direct contact are physical contacts between an influenza-infected patient (i.e., index patient or control patient, respectively) and a contact (e.g., shaking hands, etc.). Influenza A virus has been shown to survive up to 3 days when inoculated onto paper money (Thomas, Appl. Environ. Microbiol. 74.10 (2008):3002-3007). The same inoculum in the presence of respiratory mucus showed a significant increase in survival time (up to 17 days, Thomas, Appl. Environ. Microbiol. 74.10 (2008):3002-3007). When using nasopharyngeal secretions from naturally infected children, influenza virus survived for at least 48 hours in one third of cases (Thomas, Appl. Environ. Microbiol. 74.10 (2008):3002-3007). Therefore, in the context of the present invention, personal contact between a patient infected with influenza (i.e., index patient or control patient) may allow indirect contact infection. The personal contact that allows transmission by indirect contact may be the physical contact of the contactor with a fomites after the influenza-infected patient (i.e., index patient or control patient) has personal contact with the fomites. For example, the influenza-infected patient may touch the fomites with his / her hands or inhale the fomites. The period between the personal contact of the influenza-infected patient with the fomites and the personal contact of the contactor with the fomites may be 3 days or less, preferably 48 hours or less.

[0039] Respiratory viruses such as influenza virus replicate in the respiratory tract, are excreted from there, and are transmitted through respiratory secretions by airborne infection. In the present invention, personal contact that allows airborne infection is a distance of up to 3.7 meters between the influenza-infected patient (i.e., the index patient or control patient, respectively) and the contact. Influenza is mainly transmitted through respiratory droplet infection. Therefore, during personal contact between the contact and the index patient or control patient, the distance between these people (i.e., the contact and the index patient or control patient, respectively) is preferably up to 1 meter, more preferably less than 1 meter.

[0040] With the enhanced device, influenza virus can be detected immediately after infection. Usually, infection is detected one day after infection. In one embodiment of the invention, transmission from the treated index patient has occurred if influenza virus can be detected in at least one contact of the treated index patient. In a preferred embodiment of the invention, transmission from the treated index patient has occurred if influenza virus can be detected in at least one contact of the treated index patient within 15 days after administration of the compound to the index patient. In one embodiment of the invention, transmission from the treated index patient has occurred if influenza virus can be detected in at least one contact of the treated index patient within 10 days after administration of the compound to the index patient. If transmission occurs, influenza virus may be detected in contacts even for a longer period (e.g., within 15 days after administration of the compound to the index patient). If the virus is mutating, a longer course of the disease (e.g., 3 weeks or more) is particularly expected.

[0041] In one embodiment of the invention, transmission from a control patient has occurred if influenza virus can be detected in at least one contact of the control patient. In a preferred embodiment of the invention, transmission from a control patient has occurred if influenza virus can be detected in at least one contact of the control patient within 15 days of administration of other anti-influenza drugs to the control patient, or within a corresponding period of time considering the influenza disease process if the control patient was not administered the anti-influenza drugs. In one embodiment of the invention, transmission from a control patient has occurred if influenza virus can be detected in at least one contact of the control patient within 10 days of administration of other anti-influenza drugs to the control patient, or within a corresponding period of time considering the influenza disease process if the control patient was not administered the anti-influenza drugs. As mentioned above, if transmission has occurred, influenza virus may be detected in the contacts even for a longer period of time (e.g., within 15 days of administration of other anti-influenza drugs to the control patient, or within a corresponding period of time considering the influenza disease process if the control patient was not administered the anti-influenza drugs). Also as mentioned above, if the virus is mutating, a longer course of the disease (e.g., 3 weeks or more) is particularly expected.

[0042] In the context of the present invention, the transmission rate can be measured by testing at least one contact of the treated index patient or control patient, respectively, for influenza virus infection. The transmission rate can be measured by testing at least one contact of the treated index patient or control patient, respectively, within 10 days of administration of the compound to the index patient, or within 10 days of administration of other anti-influenza drugs to the subject patient, or within 10 days of the corresponding time point considering the influenza disease process if the control patient was not administered the anti-influenza drug.

[0043] Influenza is a serious disease and recovery takes several days to several weeks. Therefore, according to the present invention, the transmission rate can also be measured by testing at least one (e.g., at least two) contacts of the treated index patient or control patient for influenza virus infection within 20 days from administration of the compound to the index patient, or within 20 days from administration of other anti-influenza drugs to the control patient, or within 20 days from the corresponding time point considering the influenza disease process if the control patient was not administered the anti-influenza drug. For example, the contacts can be tested for influenza virus infection at various time points, for example, about 3 days, 5 days, 10 days, 15 days, and / or 20 days after administration of the compound to the index patient, or within 20 days from administration of other anti-influenza drugs to the control patient, or within 20 days from the corresponding time point considering the influenza disease process if the control patient was not administered the anti-influenza drug.

[0044] In one embodiment of the present invention, influenza virus infection is present if influenza virus can be detected (e.g., in contacts of index or control patients, respectively). Influenza virus can be detected via PCR. Additionally or alternatively, influenza virus can be detected by using influenza test kits. For example, Rapid Influenza Diagnostic Tests (RIDTs) can be used to detect influenza virus. RIDTs are immunoassays that can identify the presence of influenza A or B virus nucleoprotein antigens in respiratory specimens and display the results qualitatively (positive vs. negative) (Ali T, Clin Infect Dis. 2004 Mar 1;38(5):760-2). RIDT assays are ELISA-based assays that are less accurate than PCR, but have the advantage of being cheap and fast, which is of great benefit especially in epidemic and pandemic situations.

[0045] Influenza virus can be further detected using the Roche cobas® Liat® point-of-care (POC) polymerase chain reaction (PCR) system (Chen, Eur J Microbiol Immunol (Bp). 2015;5(4):236-245). The cobas® Liat® system allows for rapid and accurate diagnosis of nasopharyngeal swab specimens for influenza A or B. The system consists of the cobas® Liat® Analyzer and the cobas® Influenza A / B Assay. Influenza virus detection can also be performed using PCR-based molecular tests (Prodesse ProFlu+ assay, Chen, Eur J Microbiol Immunol (Bp). 2015;5(4):236-245) or the Alere i Influenza A&B Rapid PCR System (Merckx, Ann Intern Med. 2017;167(6):394-409).

[0046] Detection of influenza virus can further be performed by testing for the presence of infectious viral particles, for example by measuring viral titer and / or viral shedding. Viral titer (e.g., in the nasal mucosa) can be determined by plaque assay (e.g., as described in the accompanying examples and below).

[0047] Determination of the infectious titer of a virus is generally known in the art. For example, the infectious virus titer can be measured by a quantitative culture assay, i.e., a "plaque assay." In particular, the infectious titer of a virus can be expressed as the median tissue culture infectious dose per milliliter (TCID 50) can be determined in a quantitative culture assay that represents the amount of virus present. To determine the infectious titer of a given sample, clinical specimens can be serially diluted and incubated on MDCK cells. The first readout of this assay utilizes the ability of influenza virus to bind to sialylated glycans on red blood cells and cause agglutination. Measurements of agglutination mediated by adding red blood cells to a dilution series of influenza virus can then be used to quantify the viral titer. For circulating virus isolates (e.g., current isolates of each season) that have lost the ability to agglutinate red blood cells, an ELISA-based readout of influenza nucleoprotein (NP) can be applied. TCID 50 The assay can be run as a uniform protocol where NP-ELISA can be performed using the same assay plate if the virus is non-agglutinating. In clinical trials, the assay analysis using hemagglutination reading can be followed by NP-ELISA reading for influenza virus subtypes (H3, etc.) (and non-typeable viruses). For the plate to be valid, the negative control must be negative and the positive control must be positive. The Karber method (Karber, G., 1931, Beitrag zur kollektiven Behandlung Pharmakologischer Reihenversuche, Archiv fur Experimentelle Pathologie und Pharmakologie, 162, 480-487) can be used to determine the virus titer (TCID 50 ) can be calculated.

[0048] For example, to determine the viral infectivity titer, virus can first be grown from a nasal wash sample and then the viral infectivity titer can be measured as described below: Propagation of virus from nasal wash samples can be performed as follows: MDCK cells can be maintained in cell culture medium until use. One day prior to the assay, MDCK cells can be plated in 96-well flat-bottom plates at 3.5×10 per well in cell culture medium. 4 The MDCK monolayer can be seeded with 100 μL of nasal wash sample. Trypsin-EDTA may be required to detach the cells from the culture flask. Incubation for 24 h at 37 °C, 5% CO2 results in a cell monolayer at 80–100% confluency. Three 10-fold serial dilutions are made by adding 20 μL of thawed nasal wash sample to 180 μL of infection medium. The MDCK monolayer is then washed twice with PBS and 100 μL of diluted sample is added to the cells and incubated for 2 h at 37 °C, 5% CO2. The last row of the plate may be without sample as a negative control. The virus inoculum can then be removed and replaced with 200 μL of fresh infection medium. The plate can then be incubated for 96 h at 37 °C, 5% CO2.

[0049] Measurement of viral titers in nasal washes can be performed as follows. After 96 hours of incubation, viral titers of nasal wash samples cultured on MDCK plates can be read by hemagglutination assay. 25 μL of MDCK supernatant from each well is transferred to the corresponding well of a new 96-well U-bottom plate and mixed with 25 μL of 1% (v / v) turkey red blood cells by tapping. The plate is incubated at room temperature for 30 minutes and the agglutination pattern is recorded. Viral titers can be calculated using the method described by Reed and Muench (Reed, LJ and H. Muench, American Journal of Epidemiology, 1938. 27(3):p. 493-497) and are expressed as log 10 TCID 50 It can be expressed as / mL.

[0050] Additionally, the presence of at least one influenza symptom is indicative of the presence of influenza virus infection. Thus, according to the present invention, influenza virus infection is: (i) influenza virus is detectable; and / or (ii) the presence of at least one symptom of influenza virus infection; exists in the case

[0051] In one embodiment of the present invention, influenza virus infection exists when both characteristics are true, i.e. influenza virus can be detected and at least one symptom of influenza virus infection exists.Thus, the transmissibility (i.e. infectiousness) of treated index patient or control patient can be measured by testing whether influenza virus can be detected and, if necessary, further testing whether influenza symptoms exist in people who have personal contact with treated index patient or control patient, respectively.For example, it can be tested whether at least one symptom of influenza virus infection exists.The at least one symptom of influenza virus infection can be sudden onset of fever, chills, headache, muscle and / or joint pain, cough, fatigue, sore throat and / or stuffy nose. They may also test for body temperature reaching 38°C-40°C within 24 hours of the onset of influenza symptoms (Wright, Fields Virology. 5th ed. (2). Wolters Kluwer Health / Lippincott Williams & Wilkins;2007. P. 1691-1740;Monto, Arch Intern Med. 2000;160:3243-3247). Based on these symptoms, influenza virus infections tend to be severe illnesses and can be differentiated from the common cold.

[0052] As used herein, the onset of influenza symptoms is defined as any of the following: (i) the time when the body temperature first increases (at least 1°C above normal body temperature); and (ii) The time point at which the patient experienced at least one general or respiratory symptom. Preferably, the time of onset of influenza symptoms is confirmed by a body temperature reaching 38°C to 40°C within 24 hours from the above points (i) and (ii).

[0053] Additionally or alternatively, a diagnosis of influenza may be confirmed by all of the following: (i) A fever of 38°C (axillary) or higher for more than 4 hours after taking a fever reducer or, if a fever reducer is taken, before the test. (ii) At least one of the following common systemic symptoms associated with influenza of moderate or greater severity: (ii)-1 headache; (ii)-2 Feverishness or chills; (ii)-3 Muscle or joint pain; (ii)-4 Fatigue (iii) At least one of the following influenza-associated respiratory symptoms of moderate or greater severity: (iii)-1 Cough; (iii)-2 Sore throat; (iii)-3 Nasal congestion; (iii) Influenza A or B infection confirmed by a -4 P°C PCR test.

[0054] Transmission of influenza virus from an index or control patient to a contact can be confirmed by other methods. For example, transmission can be assumed to have occurred if influenza virus is detected in a contact (e.g., via PCR) and the index or control patient was the first (or only) person with influenza infection with whom the index or control patient had personal contact immediately prior to influenza virus detection in the contact (e.g., within the past 4 weeks (preferably within the past 2 weeks, more preferably within the past 7 days) immediately prior to influenza virus identification in the contact). In one embodiment of the invention, transmission from a treated index patient is confirmed when an influenza virus strain is detected in at least one contact of the treated index patient, and that influenza virus strain is identical to the influenza virus strain in the treated index patient. and transmission from a control patient is said to have occurred if an influenza virus strain is detected in at least one contact of the control patient and that influenza virus strain is identical to that of the control patient. Thus, in one aspect of the invention, transmission from a treated index patient is said to have occurred if at least one contact of the treated index patient has influenza virus infection with an influenza virus strain identical to that of the treated index patient, and transmission from a control patient is said to have occurred if at least one contact of the control patient has influenza virus infection with an influenza virus strain identical to that of the control patient.

[0055] For example, if a contact (e.g., a household contact) develops PCR-confirmed influenza A or B, a nasopharyngeal swab of the contact can be used to sequence the viral genome to test whether the influenza virus originated from the index patient or the control patient, respectively. Methods for sequencing viral genomes are generally known in the art and are also described below. A person skilled in the art will be readily in a position to determine whether the influenza virus originated from the index patient or the control patient, respectively. For example, a person skilled in the art will recognize that transmission has occurred when the viral genome of the influenza virus of the contact is identical to that of the influenza virus of the index patient or the control patient, respectively. However, the influenza virus may also mutate during or after transmission from the index patient or the control patient to the contact patient. Thus, transmission is also said to have occurred when the viral genome of the influenza virus of the contact is identical to that of the influenza virus of the index patient or the control patient, respectively, except for one to a few nucleotide differences (i.e., point mutations).

[0056] Phylogenetic trees and genetic distance measurements can be performed to determine whether transmission of influenza virus from index cases to contacts or to contacts of control cases has occurred. More specifically, the method described in Example 4 can be used to determine whether transmission has occurred.

[0057] For example, phylogenetic analyses (whole-genome trees with tree topology or bootstrap support for clustering) and / or measures of genetic distance between paired populations (e.g., L1-Norm) can be performed to identify transmission pairs. Two factors influence the outcome of the analysis. First, the amount of sequence data available. To maximize this whole genome, next-generation sequencing (WGNGS) can be performed to increase granularity and discriminatory power (compared to Sanger sequencing and / or single-gene sequencing). Second, the diversity of the sampled community / metapopulation, allowing an assessment with high confidence that viruses within a household pair are more similar to each other compared to the outer group. More sequences obtained from a community will increase the diversity of this group, making it easier to identify real transmission pairs.

[0058] For example, as described in McCrone, John T., et al. "Stochastic processes constrain the within and between host evolution of influenza virus." Elife 7 (2018):e35962, a community distribution of pairwise distances reflecting the diversity of the community can be created in 15 or more index patients (IPs), preferably at least 30 to 40 index patients (IPs), and true transmission events (e.g., household transmission events) can be inferred. As a method described for sequencing, the method described in McCrone (Elife 7 (2018):e35962) can be used. In the context of the present invention, the analysis is preferably focused on the analysis of influenza A virus samples.

[0059] Both epidemiological relatedness and genetic relatedness of the virus (e.g., within a household) can be used to define transmission pairs and eliminate confounding from background diversity in the community. A pair of individuals (e.g., within a household) may be considered as an epidemiologically related transmission pair if they have personal contact and test positive for the same subtype of influenza virus within 7 days of each other. For example, all individuals who have personal contact with each other (e.g., within a household) who developed symptoms within 7 days can be considered to be epidemiologically related. The donor of each putative pair can be defined as the person with the earlier onset of symptoms. If there were multiple donors who may have developed symptoms on the same day, the transmission event can be ignored. Donors and recipients can be assumed not to have developed symptoms on the same day (with respect to the analyzed household) unless both are index cases.

[0060] Sequence data can then be used to determine which of the epidemiologically related pairs represent true transmission events, as opposed to simultaneous community transmission. The genetic distances between influenza populations from each putative transmission pair can be measured by the L1 norm, and these distances can be compared to the distances of randomly assigned community pairs within each season. Only those with genetic distances below the 5th percentile of the community distribution of the randomly assigned pairs can be considered true transmission pairs.

[0061] As mentioned above, influenza virus is mainly transmitted by airborne infection, particularly droplet infection.Therefore, in one aspect of the present invention, influenza virus is transmitted by direct contact infection and / or airborne infection, preferably airborne infection.More preferably, transmission is droplet infection.

[0062] As described herein, the compounds used in the present invention have the advantageous property of significantly reducing the transmission of influenza virus. Thus, the compounds are particularly useful for treating certain influenza-infected patients whose infectivity should be reduced. For example, it is particularly important to reduce the infectivity of patients who may cause significant (social or economic) damage by the transmission of influenza virus. In one embodiment of the present invention, the treated index patient comes into personal contact with at least one person in an influenza risk group, or at least one person who is essential for the functioning of society after administration of the compound to the index patient and during the period of their influenza virus infection. The at least one person in the influenza risk group may be at least one person who is at high risk of influenza virus infection or at high risk of influenza-related complications. The influenza-related complications may be at least one complication selected from the group consisting of hospitalization, sinusitis, otitis media, bronchitis, and pneumonia. The at least one person who is at high risk of developing influenza-related complications may be at high risk of dying due to influenza virus infection. In one embodiment of the present invention, the at least one person who is at high risk of developing influenza-related complications is a person who: (i) suffers from chronic cardiovascular disease, chronic pulmonary disease, chronic metabolic disease, chronic renal disease, cardiopulmonary impairment, and / or immunodeficiency; and / or (ii) 65 years of age or older, or less than 5 years of age.

[0063] Additionally or alternatively, at least one of the individuals at high risk of developing influenza-related complications may be a seriously ill (eg, hospitalized) patient.

[0064] As mentioned above, in one aspect of the present invention, the index patient treated after administering compound to the index patient and during their influenza virus infection period, has personal contact with at least one person of influenza risk group, and the person of influenza risk group can be at least one person with high risk of influenza virus infection.In the context of the present invention, the at least one person with high risk of influenza virus infection can be the person who is prohibited from influenza vaccination.The at least one person with high risk of influenza virus infection can be the person with serious health threat, the young child (e.g., the child under 5 years old), the elderly (e.g., the person over 65 years old), or the person with weakened immune system.

[0065] As described above, the contact of the index case may be at least one person essential to the functioning of society. The person essential to the functioning of society may be a person essential to the functioning of a city or state. According to the present invention, the at least one person essential to the functioning of society works as an essential service provider, including fire personnel, police personnel, medical personnel, emergency response service personnel, the military, or the government.

[0066] If the infected patient is an essential service provider, staying at home during influenza virus infection may be detrimental. This is especially true during emergency situations. Thus, the index patient himself may be a person essential to the functioning of society. The treatment of such an index patient with the compound used in the present invention reduces (or even prevents) the virus from being transmitted from the index patient to others, so that the index patient does not need to stay at home during influenza virus infection. For example, the index patient may work as an essential service provider, for example, belonging to firefighting personnel, police personnel, medical personnel, or emergency response service personnel.

[0067] The index patient may be a person in an influenza epidemic or influenza pandemic situation. The index patient may also be a person in a bioterrorism threat or bioterrorism attack situation where the influenza virus plays a role in a bioterrorism threat or bioterrorism attack, respectively. In fact, the impact of pandemic influenza may be orders of magnitude greater than a typical bioterrorism scenario. Therefore, preventing or mitigating influenza transmission is of great benefit in an epidemic, pandemic, or bioterrorism situation. As mentioned above, experts expect the next influenza pandemic to be associated with a high death toll and severe illness requiring hospitalization, thus placing a great strain on medical resources. Therefore, the index patient may be a medical worker, and the treatment of the index patient with the compound may be during an influenza epidemic or influenza pandemic. Also, as mentioned above, the impact of an influenza pandemic may be greatest in developing countries where medical resources are already scarce and the general population is vulnerable due to poor health and nutritional status. Therefore, the index patient may be a person from a developing country.

[0068] Of course, it is particularly advantageous (or even necessary) to reduce the transmission rate when an index patient infected with influenza has or may have personal contact with many people. Preferably, the index patient has personal contact with many people after administration of the compound used in the present invention. In one embodiment of the present invention, the treated index patient has personal contact with many people (e.g., 10 or more people after administration of the compound (to the index patient) and while infected with influenza virus). For example, the index patient has personal contact with many people in the home or at work. In one embodiment of the present invention, the treated index patient visits a care facility (such as a nursing home, nursery school, or hospital), an educational facility (such as a school or university), a public institution, a transport facility, a vehicle, an aircraft, and / or a shop, and has personal contact with many people (e.g., 10 or more people after administration of the compound to the index patient and while infected with influenza virus).

[0069] Preferably, the transmission rate of influenza virus from the treated index patient to household contacts is reduced. Therefore, it is preferred that the treated index patient is a household contact. For example, the treated index patient lives with children (preferably children under 5 years old) in one household. Additionally or alternatively, the treated index patient has a job that involves contact with many people. It is preferred that at least one of the household contacts and / or work contacts of the treated index patient is not vaccinated against influenza.

[0070] As mentioned above, the treated index patient may have personal contact with many people, for example more than 10 people (preferably more than 30 people, more preferably more than 50 people, even more preferably more than 100 people) after administration of the compound and during the influenza virus infection. The attached examples show that the transmission rate is reduced in the treated subject immediately after administration of the compound used in the present invention. According to the present invention, the compound can be administered at least 1 hour before said personal contact. In one embodiment of the present invention, the compound is administered at least 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, 30 hours, or 32 hours before said personal contact. In this regard, a longer time interval is preferred than a shorter time interval. In the context of the present invention, the compound can be administered within 48 hours from the onset of influenza symptoms, preferably within 24 hours from the onset of influenza symptoms.

[0071] The present invention is not limited to a particular dosage of the compound of the present invention. The effective amount of the compound can be selected and / or adjusted by the attending physician according to his / her experience and applicable guidelines. However, the compound is preferably administered once as a single treatment. The compound can be administered to the patient in an appropriate dosage. The compound can be administered in a dosage range that varies depending on the patient's weight, age, sex, health, diet, time of administration, method of administration, rate of excretion, and severity of the disease. The administration regime is determined by the attending physician and clinical factors. As is well known in the medical field, the dosage of a patient depends on many factors, including the patient's size, body surface area, age, the specific compound administered, sex, time and route of administration, general health, concurrently administered drugs, and the like. However, the effective amount of the compound used in the present invention is preferably about 40 mg for patients weighing less than 80 kg and about 80 mg for patients weighing 80 kg or more. The administration of baloxavir marboxil to pediatric patients is as follows: For patients under 1 year of age: (a) if the patient is less than 4 weeks old, the effective amount may be about 1 mg / kg body weight; (b) if the patient is 4 weeks or older but less than 3 months old, the effective amount may be about 1 mg / kg body weight. (c) if the patient is 3 months or older but less than 12 months old, the effective amount may be about 2 mg / kg body weight. For patients aged 1 year or older but less than 12 years, the dosage may be based on body weight. In Japan, two Phase III clinical trials were conducted in pediatric patients aged 6 months to 12 years (Study 1618T0822 and Study 1705T0833). In the first 1618T0822 study, a single tablet of baloxavir marboxil was administered to pediatric patients aged 6 months to less than 12 years with influenza. The dosage of baloxavir marboxil is as follows: 40 kg or older: 40 mg, 20 kg to 40 kg: 20 mg, 10 kg to 20 kg: 10 mg, and 5 kg to < 10 kg: 5 mg. This dosage can also be used for pediatric newly diagnosed patients.

[0072] The present invention is also not limited to a specific route of administration of the compound. All possible routes of administration that the attending physician considers useful or necessary are within the scope of the present invention. For example, the compound can be administered orally, rectally, nasally, topically, intradermally, as an aerosol, vaginally, or parenterally, such as intramuscularly, intravenously, subcutaneously, intraarterially, or intracardially. The compound is preferably administered orally. Dosage forms for oral administration include coated and uncoated tablets, soft and hard gelatin capsules, drops, lozenges, solutions, emulsions, suspensions, syrups, elixirs, powders and granules for reconstitution, dispersible powders and granules, medicated gums, chewable tablets, and effervescent tablets. Dosage forms for parenteral administration include solutions, emulsions, suspensions, dispersions, and powders and granules for reconstitution. Dosage forms for rectal and vaginal administration include suppositories and ovulas. Dosage forms for nasal administration can be administered via inhalation and insufflation, for example, by a metered dose inhaler. Dosage forms for topical administration include creams, gels, ointments, salves, patches and transdermal delivery systems. However, the compounds used in the present invention are preferably administered in the form of tablets, more preferably oral tablets. For example, the compounds used in the present invention can be administered as 20 mg tablets and / or 40 mg tablets. The compounds used in the present invention can also be administered in the form of granules. Granules are particularly advantageous when administering the compounds to individuals who cannot swallow tablets, such as children or individuals with nasogastric tubes. Thus, individuals weighing less than 80 kg can be administered a single oral dose of two 20 mg tablets or one 40 mg tablet. Patients weighing 80 kg or more can be administered a single oral dose of four 20 mg tablets or two 40 mg tablets.

[0073] The index patient may be any human subject infected with influenza virus. The index patient is preferably at least 2 years old. More preferably, the index patient is at least 12 years old. For example, the index patient may be a human patient preferably aged 12 to 64 years old. The treated index patient is preferably healthy except for being infected with influenza virus. As mentioned above, the treated index patient preferably has at least one contact (e.g., a household contact) who has not been vaccinated against influenza. More preferably, the treated index patient has at least two contacts (e.g., a household contact) who have not been vaccinated against influenza. The contacts may be aged 2 years or older.

[0074] The control patient is an influenza-infected patient that is as similar as possible to the index patient, except that the control patient has not been treated with the compound used in the present invention. Thus, the control patient has the same or at least a similar (i.e., comparable) age and health status as the index patient, and the control patient and the index patient are infected with the same influenza virus strain.

[0075] Influenza viruses cause seasonal epidemics and, in rare cases, global pandemics. The word pandemic (from the Greek word pan meaning all and demos meaning people) describes an epidemic that affects the entire population. The compounds used in the present invention have the advantage of reducing the transmission of influenza viruses and thus reducing the risk of treated index patients leading to (or contributing to) the occurrence of an influenza epidemic or influenza pandemic. Thus, in one aspect of the present invention, the treatment (of index patients) has the effect that the treated index patients have a lower risk of causing an influenza epidemic or influenza pandemic compared to control patients. Thus, according to the present invention, the treated index patients have a reduced risk of causing an influenza epidemic or influenza pandemic compared to control patients.

[0076] Here, an "influenza pandemic" is a worldwide epidemic caused by an influenza virus to which little or no immunity exists in the human population. A pandemic is defined as an epidemic that occurs over a very large area, such as the whole world or a country. Pandemics often cross international boundaries and usually affect many people. A true influenza pandemic occurs when transmission occurs at approximately the same time. Simultaneous worldwide transmission of influenza is sufficient to define an influenza pandemic, which is consistent with the classic definition of a "worldwide epidemic." For example, a pandemic may be caused by a newly emerged influenza virus that is the result of changes within an existing influenza virus. Such changes are described in more detail below. A pandemic may be relatively mild or may cause severe illness or death. It may cause severe illness in certain risk groups that may correspond to those at risk for severe illness from seasonal influenza. However, healthy individuals may become more severely ill than with seasonal influenza.

[0077] An "influenza epidemic" is a sudden increase in the number of cases of influenza virus infection beyond what would normally be expected. An "influenza epidemic" is the widespread occurrence of influenza in a community during a particular time. An epidemic is an event of active disease spread. In contrast, the term pandemic is related to geographic spread and is used to describe a disease that affects an entire country or the entire world.

[0078] There are three types of influenza viruses: A, B, and C. Types A and B cause influenza epidemics almost every year. Influenza C is associated with sporadic, often asymptomatic infections with little or no mortality and is therefore of no public health concern. Pandemic influenza occurs only with influenza A viruses. However, influenza B viruses can cause influenza epidemics. In fact, influenza B is part of seasonal influenza epidemics. Thus, according to the present invention, the influenza virus can be influenza A virus or influenza B virus, preferably influenza A virus. It is preferred that the influenza virus is an epidemic influenza virus strain or a pandemic influenza virus strain.

[0079] Influenza pandemics and epidemics in humans occur as a result of changes in surface glycoproteins known as "antigenic shift" and "antigenic drift".

[0080] In particular, one means by which influenza viruses change is called "antigenic drift." "Antigenic drift" refers to small changes in the genes of influenza viruses that occur continually over time as they replicate. These small genetic changes usually produce viruses that are very closely related to each other and can be explained by their position on the phylogenetic tree. Viruses that are closely related to each other usually share the same antigenic characteristics, and the immune system exposed to a similar virus will usually recognize and respond to it (this is sometimes called cross-protection). However, these small genetic changes can accumulate over time and result in viruses that are antigenically different (i.e., further away on the phylogenetic tree). When this occurs, the body's immune system may not recognize viruses that could potentially cause influenza epidemics.

[0081] Another type of change in influenza viruses is called "antigenic shift". Pandemic influenza is the result of antigenic shift and occurs only in influenza A viruses. Antigenic shift is a sudden major change in influenza A viruses that results in influenza viruses with new hemagglutinin (HA) and / or new HA and neuraminidase (NA) proteins. Thus, antigenic shift results in new influenza A subtypes, or viruses with hemagglutinin (HA) or combinations of hemagglutinin (HA) and neuraminidase (NA), that have emerged from animal populations that are very different from the same subtypes in humans, and most people have no immunity to the new virus. Such a "shift" occurred in the spring of 2009, when H1N1 viruses with new combinations of genes emerged and infected people, spreading rapidly and causing a pandemic. When a shift occurs, most people have little or no protection against the new virus. Thus, antigenic shift involves a sudden change in HA and possibly NA antigens that are quite different from those that have been circulating in humans for many years. Antigenic shift results in entirely new viruses that are serologically different from previous viruses and could not have emerged by mutation of those viruses. A pandemic occurs when a large proportion of the world's population lacks immunity to the new virus (i.e., they have no or few antibodies to the HA of the new virus), allowing it to spread easily from person to person and causing severe disease. A pandemic is considered imminent when a new virus spreads rapidly beyond the community in which it was first identified. Influenza viruses are constantly changing by antigenic drift, but antigenic shift occurs only occasionally. Type A viruses undergo both changes. Type B influenza viruses change only by the more gradual process of antigenic drift.

[0082] As mentioned above, influenza pandemics are usually the result of antigenic "shift" and influenza epidemics are usually the result of antigenic "drift". Thus, in the context of the present invention, influenza viruses are antigenically different compared to the parent influenza virus strain as a result of antigenic drift and / or antigenic shift, preferably antigenic shift or both.

[0083] Those skilled in the art can easily determine whether a given influenza virus is the result of antigenic drift or antigenic shift. As mentioned above, antigenic shift is a sudden and large change in influenza A virus that results in a new combination of hemagglutinin and neuraminidase proteins in influenza A viruses that infect humans. Therefore, to determine whether an influenza A virus that infects humans is the result of antigenic shift, the combination of hemagglutinin (HA) and neuraminidase (NA) proteins of said influenza A virus can be compared with the combination of hemagglutinin (HA) and neuraminidase (NA) proteins of known influenza A viruses that infect humans. If the combination of hemagglutinin (HA) and neuraminidase (NA) proteins of the influenza A virus in question does not exist in known human-infecting influenza A viruses, then the influenza A virus in question is the result of antigenic shift.

[0084] Antigenic drift is a point mutation in the genome of a virus. A person skilled in the art can easily determine whether a given influenza virus is the result of antigenic drift by sequencing the genome of this influenza virus and comparing the obtained sequence with the viral genome sequence of a known influenza virus. Thus, to determine whether an influenza virus that infects humans is the result of antigenic drift, the viral genome sequence of said influenza virus can be compared with the viral genome sequence of a known influenza virus that infects humans. If the viral genome sequence of the influenza virus in question contains nucleotide changes (i.e., point mutations) compared to known human-infecting influenza viruses, the influenza virus in question is the result of antigenic drift.

[0085] Antigenic drift is a normal evolutionary process in which viral genomes mutate (slowly compared to antigenic drift) due to error-prone polymerases. These mutations can change the functional characteristics of the virus (e.g., the resistance of the enzyme to certain drugs). Therefore, the functional characteristics of a virus can be examined to determine whether it is the result of antigenic drift.

[0086] Besides antigenic shift, viruses with pandemic potential can also emerge through viral recycling. More specifically, examination of blood samples from people of different ages can indicate whether a particular subtype of influenza was previously circulating and, if so, approximately when it ceased to be circulating. This analysis, called seroarchaeology, supports the theory of viral recycling. Seroarchaeology has established beyond a reasonable doubt that H2 and H3 subtypes recycled in humans during the 19th and 20th centuries. Furthermore, the H1 subtype that circulated in humans between 1918 and 1957 re-emerged or "recycled" in 1978. Analysis of the RNA of viruses isolated during the 1977-78 epidemic showed that the virus was more closely related to viruses isolated in 1950 than to strains isolated since. Due to antigenic drift, it was speculated that the H1N1 virus must have re-emerged from a frozen state in nature or elsewhere. However, there is evidence that influenza viruses may remain unchanged for long periods in pigs, potentially serving as a reservoir for human infection. Thus, in the context of the present invention, an influenza strain may be a recycled virus that has previously caused an epidemic or pandemic. For example, potential recycled virus strains could be A / Hong Kong / 97(H5N1), A / New Jersey / 8 / 76(H1N1), A / USSR / 90 / 77(H1N1), A / Hong Kong / 68(H3N2), A / Hong Kong / 68(H3N2), A / Hong Kong / 68(H3N2), A / USSR / 77(H1N1), A / USSR / 77(H1N1), or A / USSR / 77(H1N1).

[0087] As mentioned above, according to the present invention, the influenza virus can be an influenza A virus or an influenza B virus (e.g., B / Minnesota / 23 / 2015). The accompanying examples surprisingly show that the compounds used in the present invention can reduce the transmission of influenza virus strains influenza A / Perth / 265 / 2009 (H1N1pdm09) and A / England / 195 / 2009. Thus, according to the present invention, the influenza virus strain is preferably an influenza A virus, more preferably an influenza A strain of H1N1 subtype (e.g., A / Perth / 265 / 2009 (H1N1pdm09) or A / England / 195 / 2009). However, the influenza A virus can also be of H2N2, H3N2, H5N1, or H7N9 subtype.

[0088] In a preferred embodiment of the present invention, the influenza virus strain does not have an I38X mutation, including an I38T mutation. Thus, it is preferred that the influenza virus stain does not have an I38T mutation. The I38T substitution is a mutation in the viral acid polymerase (PA) protein of some mutant influenza A strains. The sequence of the PA protein of an influenza A virus having an I38T mutation is shown in SEQ ID NO: 4. That is, in a preferred embodiment of the present invention, the influenza virus strain does not contain a PA protein having a sequence of SEQ ID NO: 4. Also, the influenza virus strain does not contain a PA protein that is at least 80%, preferably at least 90%, more preferably at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical in sequence to the sequence of SEQ ID NO: 4 and that contains a T at the position corresponding to position 38 of SEQ ID NO: 4. A fraction of the PA protein of an influenza A virus that contains an I38T mutation is shown in SEQ ID NO: 5. Thus, in a preferred embodiment of the present invention, the influenza virus strain does not contain a PA protein that contains a sequence of SEQ ID NO: 5.

[0089] As mentioned above, the compounds used in the present invention can be used to prevent influenza epidemics or influenza pandemics. Accordingly, the present invention relates to a method for preventing influenza epidemics or influenza pandemics, comprising administering to patients (index patients) infected with influenza virus an effective amount of a compound having formula (I) or (II) or a pharma- ceutically acceptable salt thereof to at least 10% of all influenza-infected people in a city or country's population. [ka]

[0090] Thus, the present invention relates to a compound for use in treating patients infected with influenza virus (index patients), which compound is administered to at least 10% of all influenza infected people in the population of a city or country, which compound prevents an influenza epidemic or influenza pandemic, and which compound is a compound having formula (I) or (II) or a pharmaceutically acceptable salt thereof. [ka]

[0091] As used herein, "preventing" an influenza epidemic or influenza pandemic also means reducing the outbreak of an influenza epidemic or influenza pandemic (e.g., reducing the impact of an influenza epidemic or influenza pandemic outbreak).

[0092] The accompanying examples provide simulations that demonstrate that treating 15% or 30% of the population with baloxavir marboxil prevents influenza epidemics or pandemics, respectively. Also, the accompanying examples show that the compounds used in the present invention have the beneficial effect of reducing transmission and thus reducing the likelihood of epidemics or pandemics occurring. Thus, the means and methods described herein advantageously reduce the economic impact associated with influenza infection.

[0093] As mentioned above, the situation surrounding the "bird flu" pandemic that occurred in Hong Kong in 1997 highlights the need for advance planning to ensure an appropriate response to health emergencies that are unpredictable, complex, and rapidly evolving, and are sure to involve great public anxiety. In the past, once a pandemic has begun, it has been too late to accomplish many of the important activities required to minimize the impact. Thus, planning and implementation of preparedness activities need to begin well in advance. Thus, in order to prevent an influenza pandemic, it is necessary to treat infected patients early with the compounds used in the present invention. Thus, according to the present invention, it is envisioned that even influenza epidemics are prevented by treating some of the influenza infected people (e.g., at least 10% of the influenza infected people) during seasonal influenza. In one embodiment of the present invention, the above method (i.e., the method for preventing an influenza epidemic or influenza pandemic) is for preventing an influenza epidemic, and at least 10%, preferably at least 15%, more preferably at least 20% of all influenza infected people of a city or country's population (preferably the population of a city) are treated with the compound. Along these lines, in one embodiment of the present invention, the above compounds (i.e. compounds that prevent influenza epidemics or influenza pandemics) prevent influenza epidemics, and at least 10%, preferably at least 15%, more preferably at least 20% of all influenza-infected individuals in a city or country's population (preferably an urban population) are treated with the compounds. For example, the compounds used in the present invention can be used to prevent influenza epidemics (e.g., during seasonal influenza) when at least 20% of the population has been effectively vaccinated and no more than 30% of the population is susceptible to infection.

[0094] Of course, the efficacy of the compounds used in the present invention to prevent epidemics (e.g., during seasonal influenza) or pandemics increases with the proportion of influenza-infected individuals treated with the compound. Thus, to prevent influenza epidemics (such as seasonal influenza), at least 30%, at least 40%, or at least 50% of the infected individuals in a city or country's population (preferably the urban population) can be treated with the compound.

[0095] In one embodiment of the present invention, the above method (i.e., a method for preventing influenza epidemics or influenza pandemics) is for preventing influenza epidemics, and at least 25%, preferably at least 30%, and more preferably at least 35% of all influenza infected people in the population of a country are treated with the compound. Along these lines, in one embodiment of the present invention, the above compound (i.e., a compound for preventing influenza epidemics or influenza pandemics) prevents influenza pandemics, and at least 25%, preferably at least 30%, and more preferably at least 35% of all influenza infected people in the population of a country are treated with the compound. For example, the compound used in the present invention can be used to prevent influenza pandemics in cases where effective vaccination is not available and susceptible people are 30% or less of the population. As mentioned above, the efficacy of the compound used in the present invention to prevent pandemics increases with the proportion of influenza infected people treated with the compound. Thus, to prevent influenza pandemics, at least 45%, at least 55% or at least 65% of infected people in a city or country's population can be treated with the compound.

[0096] The means and methods described herein are particularly advantageous when influenza virus strains are not resistant to the compounds used in the present invention.However, influenza virus strains may be resistant to other antiviral drugs (peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, amantadine, etc.).The test for determining whether a given virus is resistant to one or more drugs is generally known in the art, and includes, for example, phenotypic resistance assay and NA-Star assay, which are described below.

[0097] Phenotypic resistance assays can be performed as described below: Phenotypic resistance assays (spot / focus reduction assays) can be performed using the highly sensitive Virospot detection technology, which combines classical virus culture in multi-well microtiter plates and virus-specific immunostaining with automated imaging and detection of infected cells using the CTL Immunospot UV analyzer with Biospot analysis software. The Virospot technology platform is a novel platform for the detection of IC 50 / I C 90 This method determines the susceptibility of viral isolates to antiviral drugs. Briefly, the method is based on inoculating MDCK cell monolayers in 96-well plates with infectious virus in the presence of a range of drug concentrations. After incubation, cells are fixed and immunostained with virus-specific antibodies followed by TrueBlue substrate, and images are captured using a UV analyzer.

[0098] The NA-Star assay is particularly useful for determining phenotypic resistance to neuraminidase inhibitors (such as oseltamivir) and can be performed as follows: The assay uses a chemiluminescent substrate for sensitive detection of neuraminidase enzyme activity. Neuraminidase activity produces a luminescent compound that is quantified using a reader. Viral neuraminidase activity is determined in the presence of serial dilutions of a neuraminidase inhibitor. Susceptibility to neuraminidase inhibitors is determined using the IC 50 / I C 90 It is expressed as a value.

[0099] The compounds used according to the present invention can be combined with other anti-influenza drugs. Currently, four antiviral drugs are approved in the EU for the prevention and treatment of influenza: the M2 ion channel inhibitor amantadine and the NAIs oseltamivir phosphate, zanamivir, and peramivir. Another M2 inhibitor, rimantadine, has marketing authorization in the Czech Republic, France, and Poland, but is not commercially available in these countries. Thus, the compounds used according to the present invention can be administered as combination therapy with amantadine, oseltamivir phosphate, zanamivir, peramivir, and / or rimantadine. Neuraminidase inhibitors (NAIs) are the mainstay of influenza infection treatment. Thus, when the compounds used according to the present invention are administered as combination therapy, they are preferably combined with oseltamivir phosphate or zanamivir. Both oseltamivir phosphate and zanamivir are administered twice a day for five days.

[0100] As stated above, the present invention provides means and methods for reducing the transmission of influenza viruses, i.e., for reducing the infectivity of influenza-infected patients (i.e. index patients). In line with this, the present invention also relates to the following aspects: All descriptions, definitions and preferred aspects set forth above also relate, mutatis mutandis, to the aspects of the invention set forth below.

[0101] The present invention also relates to a method for treating influenza virus infection, comprising administering an effective amount of a compound to a patient infected with influenza virus (index patient), the compound being a compound having any of formulas (I) and (II) or a pharma- ceutically acceptable salt thereof, and the compound reduces transmission. The present invention also includes a method for treating influenza, comprising reading the dosage instructions on a package insert or package for a pharmaceutical preparation comprising a compound having any of formulas (I) or (II) or a pharma- ceutically acceptable salt thereof, and administering an effective amount of the compound to an influenza-infected patient (index patient) whose infectivity is to be reduced. The present invention also relates to the use of a compound having any of formulas (I) or (II) or a pharma- ceutically acceptable salt thereof for the manufacture of a medicament for treating an influenza-infected patient (index patient) whose infectivity is to be reduced. The present invention also provides a package further comprising a pharmaceutical preparation comprising a compound having any of formulas (I) or (II) or a pharma- ceutically acceptable salt thereof, and dosage instructions for administering an effective amount of the compound to an influenza-infected patient (index patient) whose infectivity is to be reduced.

[0102] As explained above, the index patient is preferably healthy except for the influenza virus infection.The index patient is preferably not treated with any other drugs than the compound used in the present invention.For example, the index patient is preferably not treated with experimental treatments, systemic antiviral drugs (e.g., peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine), immunosuppressants, corticosteroids, antifungals, or drugs administered to the eyes, nose or ears or by inhalation.

[0103] The meaning of the term "influenza virus infection" or variations thereof is generally known in the art and refers to a disease caused by influenza viruses. More specifically, influenza virus infection is an acute respiratory infection caused by viruses of the Orthomyxoviridae family. Two forms are known that primarily infect and cause disease in humans: influenza A virus and influenza B virus. Influenza viruses have a segmented, negative-sense, single-stranded, lipid-encapsulated ribonucleic acid (RNA) genome and range in size from 80 to 100 nm. Subtypes are defined by the hemagglutinin (HA) and neuraminidase (NA) glycoproteins present in the lipid coat of the virus. Influenza viruses enter respiratory epithelial cells by attachment of the viral HA to sialic acid-containing receptors on the cell membrane, followed by internalization of the virus into acidic endosomes. In the acidic environment of the endosome, the HA undergoes a conformational change to release a fusion peptide, resulting in fusion of the viral envelope with the endosomal membrane. At the same time, the matrix-2 (M2) protein functions as an ion channel, allowing hydrogen ions to enter the virion from the endosome. This allows the viral gene segments to leave the virion and enter the cytoplasm, a process known as uncoating. The viral gene segments are transported to the nucleus, where the viral polymerase complex, composed of the proteins polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2), and polymerase acidic protein (PA), directs the synthesis of a positive-sense messenger RNA (mRNA), as well as, via a positive-sense full-length complementary RNA, a negative-sense full-length copy that serves as the progeny genomic RNA. The polymerase protein also plays a role in the disruption of host cell protein synthesis. Assembly of progeny virions occurs at the plasma membrane, and the viral NA protein plays a role in viral release from the cell surface by cleavage of surface sialic acids.

[0104] The "compounds" used in the present invention are those represented by the following formulae I and II: [ka] (i.e., a compound having formula (I) or (II)) or a pharma- ceutically acceptable salt thereof. Compounds used in the present invention are also referred to herein as "compounds", "compounds for use", "compounds used (herein / in the present invention)" or "compounds of the present invention".

[0105] The compounds used in the present invention act as selective cap-dependent endonuclease (CEN) inhibitors, inhibiting the "cap-snatching" function of the PA subunit of influenza polymerase, which is used to cleave the 5' cap structure from host cell mRNAs that are used as primers for viral mRNA transcription. By inhibiting this essential function, the compounds used herein suppress influenza virus replication.

[0106] The compounds used in the present invention have a broad spectrum of activity against seasonal influenza viruses (e.g., A / H1N1, A / H3N2, and B) and highly pathogenic avian influenza viruses (e.g., A / H5N1, A / H7N9), and their antiviral activity is stronger (lower 50% inhibitory concentration [IC 50 ]). The ability of the compounds to be effective as a single dose simplifies treatment and improves patient compliance compared to neuraminidase inhibitors (NAIs). Preferably, the compounds have formula (I) or (II), most preferably formula (I). Compounds of formula (I) can be represented as follows: [ka]

[0107] The molecular formula of this compound (i.e., the compound of formula (I)) is 27 H 23F2N3O7S. This compound is a prodrug known as baloxavir marboxil. Baloxavir marboxil is known in the art and is described, for example, in Noshi, Antiviral research 160 (2018):109-117.

[0108] Baloxavir marboxil (i.e., the compound of formula (I)) is an anti-influenza virus drug with a novel mechanism of action. The compound was discovered and is being developed by Shionogi & Co., Ltd. and F. Hoffman-La Roche, Ltd. Baloxavir marboxil (S-033188) is a prodrug that is converted to its active form (S-033447) by metabolism (hydrolysis). The active form is represented herein by formula (II). The active form (S-033447) selectively inhibits cap-dependent endonuclease (CEN) activity required for influenza virus replication (Omoto, Sci Rep. 2018;8(1):9633). Broad activity against seasonal influenza viruses and mitigating effects on influenza symptoms have been demonstrated in nonclinical efficacy studies and clinical trials in influenza patients. These studies include a phase 2 proof of concept (POC) and dose-finding study, a phase 3 double-blind study in otherwise healthy patients (Portsmouth S, Kawaguchi K, Arai M, Tsuchiya K, Uehara T. Cap-dependent endonuclease inhibitor S-033188 for the treatment of influenza: results from a phase 3, randomized, double-blind, placebo- and active-controlled study in otherwise healthy adolescents and adults with seasonal influenza. Abstract LB-2. Oral presentation at ID Week 2017, October 4-8 2017, San Diego, CA, USA), and a phase 3 open-label study in otherwise healthy pediatric patients.

[0109] The compound of formula (II) is the active form of baloxavir marboxil (i.e., the prodrug of formula (I)). The compound of formula (I) may also be represented as follows: [ka]

[0110] The compound of formula (II) is also known as baloxavir acid, which is known in the art and is described, for example, in Noshi, Antiviral research 160 (2018):109-117.

[0111] Pharmaceutically acceptable salts of the compounds used in the present invention include, for example, salts with alkali metals (e.g., lithium, sodium, potassium, etc.), alkaline earth metals (e.g., calcium, barium, etc.), magnesium, transition metals (e.g., zinc, iron, etc.), ammonia, organic bases (e.g., trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, pyridine, picoline, quinoline, etc.) or amino acids, or salts with inorganic acids (e.g., hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid, etc.) or organic acids (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, etc.). Particular mention may be made of the salts with sodium, potassium, calcium, magnesium, iron, etc. These salts may be formed in the usual manner.

[0112] The preparation of the compounds of the present invention is well known in the art.For example, the compounds of the present invention can be prepared by the method described in patent application PCT / JP2016 / 063139, which is published under the title WO2016 / 175224A1.

[0113] As mentioned above, according to the present invention, it is preferred that the influenza virus strain does not contain a PA protein having a sequence with at least 80%, preferably at least 90%, more preferably at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to the sequence of SEQ ID NO: 4, and containing a T at the position corresponding to position 38 of SEQ ID NO: 4. In particular, to assess the degree of identity between two viral PA proteins, FASTA sequences of the two sequences of viral PA proteins can be generated and aligned. To determine the percentage of identity of the two sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of the first and second amino acid sequences for optimal alignment, and non-homologous sequences can be ignored for comparison purposes). The percentage of identity between the two sequences is a function of the number of identical positions shared by both sequences, taking into account the number of gaps and the length of each gap that needs to be introduced for optimal alignment of the two sequences.The percent identity between two polypeptide / amino acid sequences can be determined using, for example, the Smith Waterman Alignment (Smith, TF and MS Waterman (1981) J Mol Biol 147:195-7); GeneMatcherPlus™ integrated "BestFit" (Smith and Waterman, Advances in Applied Mathematics, 482 489 (1981)), Schwarz and Dayhof (1979); Atlas of Protein Sequence and Structure, Dayhof, MO, Ed, pp 353-358; BLAST programs (Basic Local Alignment Search Tool; (Altschul, SF, W. Gish, et al. (1990) J Mol Biol 215:403-10), BLAST-2, BLAST-P, BLAST-N, BLAST-X, WU-BLAST- 2, ALIGN, ALIGN-2, It can be determined by various methods known by those skilled in the art using publicly available computer software, such as CLUSTAL, or Megalign (DNASTAR) software.In addition, those skilled in the art can determine the appropriate parameters for measuring alignment, including the algorithm required to achieve maximum alignment over the length of the sequences compared.Preferably, viral PA protein sequences are compared over their entire length.For the purpose of the present invention, sequence comparison and determination of percent identity between two sequences can be performed using Brossum 62 scoring matrix (gap penalty 12, gap extension penalty 4, frameshift gap penalty 5).

[0114] As mentioned above, one aspect of the present invention relates to a pharmaceutical composition comprising a compound having any of formulas (I) and (II), or a pharma- ceutically acceptable salt thereof, and optionally a pharma- ceutically acceptable carrier, for preventing (e.g., reducing) the transmission of influenza viruses. The pharmaceutical composition can be formulated with a pharma- ceutically acceptable carrier by known methods. For example, the composition can be formulated by appropriately combining the ingredients with a pharma- ceutically acceptable carrier or vehicle, specifically, sterile water or saline, vegetable oil, emulsifier, suspending agent, surfactant, stabilizer, flavoring agent, excipient, vehicle, preservative, binder, etc., by mixing them in a unit dose and form required for the implementation of a generally accepted pharmaceutical product. Specific examples of carriers include light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl acetal diethylaminoacetate, polyvinylpyrrolidone, gelatin, medium-chain triglyceride, polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethyl cellulose, corn starch, inorganic salts, etc. The content of the active ingredient in the formulation is adjusted so as to obtain an appropriate dose within the required range.

[0115] The pharmaceutical composition may optionally include one or more pharma- ceutically acceptable additives, such as a carrier, a diluent, a filler, a disintegrant, a lubricant, a binder, a colorant, a pigment, a stabilizer, a preservative, an antioxidant, or a dissolution enhancer. The pharmaceutical composition may also include, for example, poly(ethylene glycol) having a molecular weight in the range of about 200 to about 5,000 Da, ethylene glycol, propylene glycol, a nonionic surfactant, tyloxapol, polysorbate 80, macrogol-15-hydroxystearate, a phospholipid, lecithin, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, cyclodextrin, hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, dihydroxypropyl-β-cyclodextrin, glucosyl-α-cyclodextrin, glycer ... In some embodiments, the solubility enhancer may include one or more solubility enhancers, such as glycerol, glucosyl-β-cyclodextrin, diglucosyl-β-cyclodextrin, maltosyl-α-cyclodextrin, maltosyl-β-cyclodextrin, maltosyl-γ-cyclodextrin, maltotriosyl-β-cyclodextrin, maltotriosyl-γ-cyclodextrin, dimaltosyl-β-cyclodextrin, methyl-β-cyclodextrin, carboxyalkyl thioethers, hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, vinylaceto copolymer, vinylpyrrolidone, sodium lauryl sulfate, dioctyl sodium sulfosuccinate, or any combination thereof.

[0116] Pharmaceutical composition is not limited to the means and methods described herein.Those skilled in the art can use the knowledge of those skilled in the art available in the art to construct suitable composition.Specifically, pharmaceutical composition can be formulated by the techniques known to those skilled in the art, such as the techniques published in Remington's Pharmaceutical Sciences, 20th Edition.

[0117] The contents of all references cited herein above and below are incorporated by reference in their entireties.

[0118] The invention is further illustrated by reference to the following non-limiting figures and examples. [Brief description of the drawings]

[0119] [Figure 1] Time course and study design for Example 1. Time course of the experiment for Example 1. Baloxavir was administered once as a subcutaneous dose (1 mg / kg suspension in four different locations on the back of the ferret). Oseltamivir phosphate (5 mg / kg) was administered orally twice daily for five days. See text for details. DF, donor ferret; SF, sentinel ferret; DC, direct contact; RD, respiratory droplets. [Diagram 2] Plaque Assay Results for Example 1. (A) Control ferrets. All control ferrets were influenza positive as detected by plaque assay (donor: 4 / 4; Sentinel DC: 4 / 4; Sentinel RD: 3 / 4, where all (4 / 4) were positive in the RT-PCR assay). (B) Ferrets treated with oseltamivir. All ferrets treated with oseltamivir were influenza positive as detected by plaque assay (donor: 4 / 4; Sentinel DC: 4 / 4; Sentinel RD: 3 / 4, where all (4 / 4) were positive in the RT-PCR assay). (C) Ferrets treated with baloxavir. Only one Sentinel baloxavir ferret was infected by respiratory droplet infection as detected by plaque assay (donor: 3 / 4, where all (4 / 4) were positive in the RT-PCR assay; Sentinel DC: 4 / 4; Sentinel RD: 1 / 4). DF, donor ferret; SF, sentinel ferret; DC, direct contact; RD, respiratory droplets. [Diagram 3]qRT-PCR results for Example 1. (A) Control ferrets. All control ferrets were influenza positive as detected by qRT-PCR (donor: 4 / 4; Sentinel DC: 4 / 4; Sentinel RD: 4 / 4). (B) Ferrets treated with oseltamivir. All ferrets treated with oseltamivir were influenza positive as detected by qRT-PCR (donor: 4 / 4, Sentinel DC: 4 / 4, Sentinel RD: 4 / 4). (C) Ferrets treated with baloxavir. Only one Sentinel baloxavir ferret was infected by respiratory droplets as detected by qRT-PCR (donor: 4 / 4; Sentinel DC: 4 / 4; Sentinel RD: 1 / 4). (D) Summary of qRT-PCR results. Only one Sentinel baloxavir ferret was infected by respiratory droplets as detected by qRT-PCR. DF, donor ferret; SF, sentinel ferret; DC, direct contact; RD, respiratory droplets. [Figure 4] Time course of experiment 1 in Example 2. Baloxavir was administered by a single treatment consisting of 1 mg / kg subcutaneous injection (injected at 4 sites on the ferret's back (total 4 mg / kg)). Placebo (suspension vehicle only at 1 mL / kg) was administered in the same manner. Oseltamivir phosphate (5 mg / kg) was administered orally twice daily until endpoint (except for the last day). Treatment of donor ferrets: 24 hours after donor inoculation. Co-housing of recipient ferrets: 24 hours after donor inoculation. See text for details. BXA, baloxavir; OST, oseltamivir. [Diagram 5]TCID50 of donor ferrets in experiment 1 of Example 2. 0 / 4 baloxavir-treated donors shed detectable infectious virus at the 3 DPI (3 days post infection) endpoint. Titers in the baloxavir group were significantly lower than the placebo group at 2 DPI (*p≦0.05) and 3 DPI (***p≦0.001). 4 / 4 oseltamivir-treated donors and 4 / 4 placebo-treated donors shed infectious virus at the 3 DPI endpoint. There were no significant differences in group titers observed between oseltamivir-treated and placebo-treated donors. BXA, baloxavir; OST, oseltamivir. [Figure 6] qRT-PCR results for donor ferrets from experiment 1 of Example 2. Viral RNA is present in nasal washes of all animals at all sampling points. Viral copy numbers in the baloxavir (*) and oseltamivir (+) groups at 3 DPI were significantly reduced compared to the placebo group (p≦0.05). The copy number threshold for detecting positivity was based on the lowest RNA copy number standard resulting in a Ct value of less than 35 per assay. Pharmacokinetics (PK) of the baloxavir group at 48 hours post-treatment was 10.2±2.8 ng / mL of baloxavir ±SD in plasma. BXA, baloxavir; OST, oseltamivir. [Figure 7] Recipient ferret results for experiment 1 of Example 2. (A) TCID50 results. 1 / 4 ferrets in the baloxavir group shed detectable infectious virus after contact exposure to the donor, compared to 4 / 4 in the oseltamivir group and 4 / 4 in the placebo group. (B) qRT-PCR results. 2 / 4 ferrets in the baloxavir group had detectable influenza virus RNA, compared to 4 / 4 in the oseltamivir group and 4 / 4 in the placebo group. BXA, baloxavir; OST, oseltamivir. [Figure 8]Time course of experiment 2 in Example 2. Baloxavir was administered by a single treatment consisting of 1 mg / kg subcutaneous injection (injected at 4 sites on the ferret's back (total 4 mg / kg)). Placebo (suspension vehicle only at 1 mL / kg) was administered in the same manner. Oseltamivir phosphate (5 mg / kg) was administered orally twice daily until endpoint (except for the last day). Donor treatment: 24 hours after donor inoculation. Recipient co-housing: 48 hours after donor inoculation. See text for details. BXA, baloxavir; OST, oseltamivir. [Figure 9] Donor ferret results for experiment 2 in Example 2. (A) TCID50 results. 0 / 4 baloxavir-treated donors shed detectable infectious virus at the 4 DPI endpoint. Titers in the baloxavir group were significantly lower than those in the placebo group at 2 DPI (*p≦0.05), 3 DPI (**p≦0.001), and 4 DPI (***p≦0.001). Titers in the baloxavir group were significantly lower than those in the oseltamivir group at 3-4 DPI (p≦0.01). However, titers immediately prior to treatment (i.e., 1 DPI) were significantly higher in the baloxavir group than in the placebo group (p≦0.001). 4 / 4 oseltamivir-treated donors and 4 / 4 placebo-treated donors shed infectious virus at the 4 DPI endpoint. Titers in the oseltamivir group were significantly lower (p ≤ 0.05) than the placebo group at 1 (DPI), but there was no difference at 2–4 DPI. (B) qRT-PCR results. Viral RNA was present in the nasal washes of all animals at all sampling points. The mean viral copy number was reduced in the baloxavir group at 3 DPI, but no differences were observed at other days. Pharmacokinetics (PK) of the baloxavir group at 72 h posttreatment was 12.5 ± 2.4 ng / mL of baloxavir ± SD in plasma. XA, baloxavir; OST, oseltamivir. [Figure 10]Recipient ferret results for experiment 2 of Example 2. (A) TCID50 results. 1 / 4 recipient ferrets in the baloxavir group shed detectable infectious virus after contact exposure to the donor, compared to 4 / 4 in the oseltamivir group and 4 / 4 in the placebo group. (B) qRT-PCR. 1 / 4 recipient ferrets in the baloxavir group had detectable influenza virus RNA, compared to 4 / 4 in the oseltamivir group and 4 / 4 in the placebo group. (C) Serology. 2 / 4 recipient ferrets in the baloxavir group showed antibody responses to the donor virus, compared to 4 / 4 in the oseltamivir group and 4 / 4 in the placebo group. Antibody responses detected in TCID50-negative ferrets were reduced (>32-fold change) compared to TCID50-positive ferrets. "-": no antibody response was observed. [Figure 11] Time course of experiment 3 in Example 2. Baloxavir was administered by a single treatment consisting of 1 mg / kg subcutaneous injection (injected at 4 sites on the ferret's back (total 4 mg / kg)). Placebo (suspension vehicle only at 1 mL / kg) was administered in the same manner. Oseltamivir phosphate (5 mg / kg) was administered orally twice daily until endpoint (except for the last day). Donor treatment: 48 hours after donor inoculation. Recipient co-housing: 48 hours after donor inoculation. See text for details. BXA, baloxavir; OST, oseltamivir. [Figure 12]Donor ferret results for experiment 3 in Example 2. (A) TCID50 results. No baloxavir-treated donors were shedding infectious virus at the 4 DPI endpoint (i.e., 0 / 4). Group titers for the baloxavir group were significantly lower than the placebo group at 3 and 4 DPI (**p≦0.001) and lower than the oseltamivir group at 4 DPI (p≦0.001). All (i.e., 4 / 4) oseltamivir-treated donors and all (i.e., 4 / 4) placebo-treated donors shed infectious virus at the 4 DPI endpoint. The titers for the oseltamivir group were significantly lower than the placebo group titers at 3 DPI (p≦0.05). (B) qRT-PCT results. Viral RNA present in nasal washes of all animals at all sampling points was measured. There were no significant differences between the mean copy numbers of the groups. Pharmacokinetics (PK) of the baloxavir group at 72 hours post-treatment was 24.5 ± 4.03 ng / mL of baloxavir ± SD in plasma. XA, baloxavir; OST, oseltamivir. [Figure 13] Recipient ferret results for experiment 3 of Example 2. (A) TCID50 results. 2 / 4 donor ferrets in the baloxavir group shed infectious virus at the 4 DPI endpoint, compared to 4 / 4 in the oseltamivir group and 4 / 4 in the placebo group. (B) qRT-PCR. 3 / 4 donor ferrets in the baloxavir group had detectable viral RNA, compared to 4 / 4 in the oseltamivir group and 4 / 4 in the placebo group. (C) Serology. Sera from recipients in all groups showed antibody responses to donor virus. TCID50-negative baloxavir group recipients (2 / 4) showed reduced antibody titers (>16-fold change) compared to TCID50-positive ferrets. "-": no antibody response was observed. *Ferret 11333 (placebo) was excluded from serology analysis as it reached a humane endpoint at 4 DPE. [Figure 14]Summary of the effect of baloxavir on donor ferrets in Experiments 1-3 of Example 2. Baloxavir treatment rapidly reduces infectious virus shedding in the upper respiratory tract. Ferrets treated with baloxavir did not shed detectable infectious virus at the donor endpoint in each experiment. [Figure 15] Summary of the effect of baloxavir on contact infection in experiments 1-3 of Example 2. In the model used, the placebo group shows a 100% frequency of contact infection with A / Perth / 265 / 2009 in naive ferrets. The oseltamivir-treated group does not reduce contact infection in naive ferrets. 100% of oseltamivir recipients show evidence of infection by TCID50, qRT-PCR, and serology under all experimental conditions. The baloxavir-treated group reduces the frequency of contact infection compared to the oseltamivir or placebo groups. Baloxavir treatment at 1 DPI reduces the frequency of infectious virus shedding in recipients to 25%. No differences were observed when cohousing of recipients was delayed by 24 hours. Baloxavir treatment at 2 DPI reduces the frequency of infectious virus shedding in recipients to 50%. However, viral copies and serum antibody responses were detected in recipients in the baloxavir group, and there was no evidence of infectious viral shedding in the upper respiratory tract (URT), indicating exposure to the virus but not infection. [Figure 16] Simulation of seasonal influenza epidemic prevention with baloxavir treatment. See text for details. [Figure 17] Simulation of influenza pandemic prevention with baloxavir treatment. See text for details. [Figure 18] CARIFS score (Canadian Acute Respiratory Illness and Flu Scale) EXAMPLES

[0120] Example 1: Baloxavir marboxil prevents respiratory droplet transmission Study design The study design for this experiment is shown in Figure 1(A) and (B). In this experiment, baloxavir was administered subcutaneously to ferrets (1 mL / kg of suspension injected at four sites on the back). Oseltamivir phosphate (5 mg / kg) was administered orally twice daily for 5 days. The study was designed with three arms, baloxavir, oseltamivir and no drug, with four groups in each arm. Each group had donor animals and sentinel animals exposed to the infected donors either by direct contact or respiratory droplet route. The experiment was carried out as follows: Day 0: All animals were implanted with a temperature monitoring and identification chip. Four ferrets (donors) were infected with influenza A virus. Under light anesthesia (ketamine / xaridine), wild type (RG) A / England / 195 / 2009 was injected for 10 min. 4 A total volume of 200 microliters was administered intranasally at a dose of pfu. Day 1: Twenty-four hours after infection, four infected ferrets were subjected to nasal washes. Nasal washes were immediately assayed for infectious virus by plaque plating on fresh MDCK cells and for viral RNA load by RT-PCR. Each donor ferret was then treated with either baloxavir, oseltamivir phosphate, or vehicle alone. Baloxavir was administered subcutaneously at four sites on the back at 1 mg / 1 mL / kg per injection (total 4 mg / 4 mL / kg). Blood samples (minimum 200 μl) were collected from donor animals at 48 and 144 hours, respectively, for pharmacokinetic (PK) analysis. Oseltamivir phosphate was administered orally at 5 mg / kg twice daily for 5 days (considered to be equivalent to the standard treatment dose of 75 mg for adults (J Antimicrob Chemother 2014; 69: 2458-2469)). After drug administration on day 1, one sentinel animal was introduced into the same cage as each infected donor (DC animals) and one sentinel animal was introduced into an adjacent cage (RD animals). Sentinel animals were not treated with drug. Day 2: All ferrets were nasally washed on day 2 and daily thereafter until the end of the experiment, in RD animals, then DC animals, and then donors. Plaque assays were performed immediately after nasal washing. Viral RNA was also monitored by RT-PCR. Clinical signs, including temperature, weight loss, and respiratory symptoms, were observed daily. In addition, virus shed in the exhaled breath from the four donor animals was monitored by placing them in a chamber for 10 min and sampling the air using sentinel MDCK cells. Day 4: In the morning, four DC and four RD animals were removed and housed separately, so sentinels were exposed from 1 to 4 days (72 h) after donor infection. The experiment was terminated when nasal washes from all animals were negative for virus on two consecutive days.

[0121] material and method Animal testing Female ferrets (20–24 weeks of age) weighing 750–1000 g were used. After acclimation, serum was collected and tested for antibodies against A / England / 195 / 09, pandemic H1N1, by HAI. At the start of the experiment, all ferrets were negative for influenza antibodies. Body weights were measured daily. Strict procedures were followed to prevent aberrant cross-contamination between animals. Sentinel animals were handled before inoculated animals, and work surfaces and operator gloves were decontaminated between animals. For inoculation, ferrets were treated with ketamine (22 mg kg -1 ) and xylazine (0.9 mg kg -1 ) and inoculated intranasally with virus diluted in PBS (0.1 ml per nostril). All animals were conscious and underwent daily nasal lavage by instilling 2 ml of PBS into the nostrils, and the effluent was collected in a modified 250 ml centrifuge tube. Nasal lavage effluent was used for virus titration by plaque assay. The detection limit of virus in the plaque assay was 10 p.fu ml -1 It was.

[0122] Ferret monitoring and activity measurement Ferrets were weighed daily after infection. Body temperature was measured daily via a subcutaneous IPTT-300 transponder (Plexx BV, The Netherlands). Ferret activity was recorded manually at the same time each day. This scoring was based on previous publication Oh DY, Barr IG, Hurt AC (2015) PLoS ONE 10(3): e0118780. Ferrets were observed in their cages for at least 4 h after nasal irrigation to minimize disturbance of activity.

[0123] cell MDCK cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco, Invitrogen) supplemented with 10% FBS and 1% penicillin / streptomycin (Sigma-Aldrich).

[0124] Plaque assay Plaque assays were performed using MDCK cells. Cell layers inoculated with 100 μl of serially diluted samples were overlaid with 0.6% agarose (Oxoid) in DMEM supplemented with 2 μg / ml trypsin (Worthington) and incubated at 37°C for 3 days.

[0125] Sample preparation for real-time PCR 140 μl of ferret nasal wash was used to extract RNA using the Qiagen Viral RNA Mini Kit (Cat. No. / ID: 52904) according to the manufacturer's instructions.

[0126] Real-time PCR Real-time PCR was performed using a 7500 Real-time PCR System (ABI) with AgPath-ID™ One-Step RT-PCR Reagents 10 μl RT-PCR Buffer (2X) (Thermo Fisher, Cat. No. 4387391), 4 μl RNA, 0.8 μl forward primer (5' GACCRATCCTGTCACCTCTGA 3', SEQ ID NO:1) and reverse primer (5'AGGGCATTYTGGACAAAKCGTCTA 3', SEQ ID NO:2) and 0.4 μl probe (5'FAM-TCGAGTCCTCGCTCACTGGGCACG-BHQ1 3', SEQ ID NO:3) in a 20 μl reaction. Reverse transcription was performed at 45°C for 10 min. PCR amplification conditions consisted of an initial denaturation step at 95°C for 10 min, followed by 95°C for 15 s and 60°C for 1 min. A total of 40 cycles were performed. For each sample, the Ct value of the target M gene was determined. The M gene is an influenza gene that encodes two matrix proteins, M1 and M2. The M gene can be detected by PCR and used to quantify influenza virus. Based on the standard curve, absolute copy numbers were calculated to confirm whether ferrets were positive for influenza A.

[0127] Ethics statement All work performed was approved by the local Genetic Manipulation (GM) Safety Committee of Imperial College London, St. Mary's Campus (centre number GM77), and the UK Health and Safety Executive. All animal experiments described in this study were carried out under UK Home Office licence, P48DAD9B4.

[0128] All of the above methods are generally known in the art and are described, for example, in "Contact transmission of influenza virus between ferrets imposes a looser bottleneck than respiratory droplet transmission allowing propagation of antiviral resistance." Frise R, Bradley K, van Doremalen N, Galiano M, Elderfield RA, Stilwell P, Ashcroft JW, Fernandez-Alonso M, Miah S, Lackenby A, Roberts KL, Donnelly CA, Barclay WS. Sci Rep. 2016 Jul 19;6:29793. doi: 10.1038 / srep29793. PMID:27430528.

[0129] Results and Discussion The results of Example 1 are shown in Figures 2 and 3. These results indicate that respiratory droplet transmission occurred less frequently in subjects treated with baloxavir compared to subjects treated with oseltamivir or placebo (i.e., 25% versus 100% transmission rate). Furthermore, a delayed time to shedding was observed in sentinel animals exposed to donors treated with either oseltamivir or baloxavir compared to controls: mean time to viral shedding was 4.25 days compared to 5.5 days for direct-contact sentinels exposed to donors treated with either oseltamivir or baloxavir. For sentinels exposed via respiratory droplets, mean time to viral shedding from untreated donor animals was 4.5 days compared to 9.3 days for oseltamivir-treated animals and 8 days for one baloxavir-treated sentinel infected via the RD route. Taken together, this indicates that baloxavir treatment of donor ferrets infected with pH1N1 2009 virus delayed transmission to co-housed sentinel ferrets and reduced the likelihood of transmission by the respiratory droplet route.

[0130] Example 2: Baloxavir marboxil prevents direct contact infection material and method Antiviral and Medication Active baloxavir acid (S-033447, hereafter BXA) and its prodrug oseltamivir phosphate (hereafter OST) were provided by Shionogi & Co., Ltd. The vehicle for BXA delivery was 0.5 w / v% methylcellulose (Sigma-Aldrich, Australia) aqueous solution (hereafter MC solution) prepared in sterile water. BXA suspended in MC solution (1 mg / mL) was prepared using a mortar and pestle and administered to reversibly anesthetized animals in a single treatment consisting of four subcutaneous injections at four sites on the back (total dose 4 mg / kg animal). Animals in the placebo group were administered in the same manner using only MC solution (1 mL / kg). OST doses (10 mg / mL) were prepared in sugar solution (1 g / mL) and administered twice daily (8 h apart) by oral route to unsedated ferrets (total dose 10 mg / kg / day).

[0131] Cells and viruses Madin-Darby Canine Kidney (MDCK) cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% (v / v) fetal bovine serum, 2 mM GlutaMAX, 0.05% sodium bicarbonate, 100 μM MEM non-essential amino acids, 20 mM HEPES, and 50,000 U penicillin-streptomycin (complete mixture referred to as "growth medium"). Influenza A / Perth / 265 / 2009 H1N1pdm09 virus was used to inoculate animals. The virus was isolated from a clinical specimen (Lab#910894) at the World Health Organization Collaborating Centre for Influenza Research (WHOCCRRI, Melbourne, Australia). The virus was plaque purified and propagated in MDCK cells.

[0132] animal Outbred male ferrets (Mustela purtorius furo), over 12 weeks of age and weighing 600–1800 g, were obtained from an independent breeder and confirmed to be serologically negative for recent circulating influenza antigens (A / Michigan / 45 / 2015, A / Singapore / INFIMH-16-0019 / 2016, B / Phuket / 3073 / 2013, B / Brisbane / 60 / 2008) by hemagglutination inhibition (HI) assay. An identification / temperature monitoring chip (LifeChip, Bio-Thermo) was implanted subcutaneously in the dorsal region of each ferret. Animals were monitored at least once daily for changes in body temperature and weight, fed pelleted food (Eukanuba) and water ad libitum, and provided with supplemental wet food (Hill's Pet Nutrition, Australia) when ethically required (<90% of baseline weight). Periodic sample collection was performed under sedation using intramuscular injections of xylazine (5 mg / kg) (Troy Laboratories), while virus inoculation and subcutaneous drug administration were performed under reversible anesthesia using intramuscular injections of a combination of ketamine (10 mg / kg) (Troy Laboratories) and medetomidine (0.02 mg / kg) (Troy Laboratories) antagonized by midazolam (0.5 mg / kg) (Troy Laboratories) and atipamezole (0.01 mg / kg) (Troy Laboratories). At endpoint, ferrets were euthanized with an intramuscular injection of irreversible anesthetics consisting of ketamine (up to 25 mg / kg) and xylazine (up to 5 mg / kg) and an overdose of pentobarbitone sodium (Troy Laboratories) (up to 1,000 mg / kg) via intracardiac injection.

[0133] Ferret studies were conducted in the Biological Resources Facility (Physical Containment Level 2) at the Peter Doherty Institute (Melbourne, Australia) in accordance with the Australian Government's National Health and Medical Research Council's Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (8th Edition). Study procedures were approved by the Departments of Biochemistry and Molecular Biology, Dental Science, Medicine, Microbiology and Immunology, and Surgery Animal Ethics Committees at the University of Melbourne (AEC#1714278).

[0134] Virology Nasal wash samples were analyzed using TCID 50 They were stored at -80°C with 1% w / v bovine serum albumin (BSA) prior to assay for viral titer. Briefly, samples were serially diluted 10-fold in serum-free growth medium containing TPCK-treated trypsin (4 μg / mL; Sigma-Aldrich) and added (in triplicate) to flat-bottom 96-well plates containing confluent monolayers of MDCK cells in each well. After infection, cells were maintained in serum-free growth medium (containing 4 μg / mL TPCK-treated trypsin) at 37°C and 5% CO2 for 96 h, after which viral growth was assessed by hemagglutination assay using 1% turkey red blood cells (RBCs). TCID 50 Titers were calculated using the Reed and Muench (1938) method (Reed, LJ, and Muench, H. (1938), American Journal of Epidemiology 27, 493-497).

[0135] Quantitative real-time RT-PCR Viral RNA was extracted from 200 μL nasal wash samples using the NucleoMag VET isolation kit (Macherey Nagel) on a KingFisher Flex (ThermoFisher Scientific) platform according to the manufacturer's instructions. Influenza virus M gene copy numbers in 4 μL of RNA were determined by quantitative real-time RT-PCR using the SensiFAST probe Lo-ROX One-Step qRT-PCR System kit (Bioline) on an ABI 7500 Real-Time PCR System (Applied Biosystems) under the following conditions: 45 °C for 10 min, 1 cycle; 95 °C for 2 min, 1 cycle; 95 °C for 5 s then 60 °C for 30 s, 40 cycles. Sample RNA was quantified using influenza A RNA standards of known copy number provided by Seqirus, Australia. Universal influenza A real-time primer / probe set was provided by the CDC Influenza Branch (Atlanta, USA) (sequences available upon request). The results were analyzed by 7500 Fast System SDS software v1.5.1.

[0136] Serology Serum was collected from end-point recipient blood samples by centrifugation and treated with receptor-destroying enzyme (RDE) (Denka Seiken) according to the manufacturer's instructions to remove nonspecific agglutination inhibitors. Treated serum was adsorbed to turkey red blood cells prior to HI assay to remove nonspecific agglutination factors. Briefly, serum (initial 1:20 dilution) was serially diluted 2-fold in PBS in V-bottom 96-well plates (last row was left as PBS negative control). A / Perth / 265 / 2009 virus adjusted to 4 hemagglutination units in 25 μL was mixed into all sample wells and incubated for 1 h at room temperature followed by incubation with 1% turkey RBCs for 45 min. Positive inhibition was defined as the appearance of a running "teardrop" pattern comparable to the PBS negative control. HI titers were calculated as the reciprocal of the highest serum dilution at which agglutination was inhibited.

[0137] Kinetic analysis of antiviral drugs End-point BXA- and placebo-treated donor blood samples were collected in heparinized tubes and plasma was separated by centrifugation. Plasma samples were stored at -80°C until transport to the Shionogi & Co., Ltd. analytical facility.

[0138] statistical analysis Data analysis was performed using Graphpad Prism (GraphPad Software, v5.01). Viral titers in daily post-inoculation / challenge nasal washes of all ferrets were compared by matched two-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. Quantitative real-time RT-PCR was performed on influenza control RNA of known copy number to generate a standard curve (linear regression of influenza cycle threshold (Ct) value vs copy number). Viral copy numbers present in nasal wash RNA samples in the same assay were calculated using the standard curve equation. Influenza A copy numbers in each group of ferrets were compared by matched two-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. p<0.05 was considered statistically significant.

[0139] Study design The time courses of Experiments 1 to 3 are shown in Figures 4, 8, and 11. Experimental groups and treatment schedule The study consisted of three separate experiments using different schedules of antiviral treatment and timing of co-housing of naive animals. In each experiment, 24 ferrets were randomly assigned to three groups (n=8): BXA, OST, or placebo. In each group, n=4 ferrets were treated donor ferrets and n=4 were naive recipients. At 0 DPI (days post inoculation) in each experiment, all donor ferrets (housed individually) were inoculated with influenza A / Perth / 265 / 2009 in 40 μL of phosphate-buffered saline (PBS) for 10 min. 3 50% Tissue Culture Infectious Dose (TCID 50) were inoculated intranasally. As above, BXA and placebo donors received a single antiviral treatment, while OST donors received daily treatment (except cull day) until endpoint. At the indicated time points, naive recipient ferrets were housed (1:1 per cage) with treated donor ferrets and exposed for 48 hours.

[0140] Experiment 1 Antiviral treatment of all donors was initiated 1 DPI, and naïve recipient ferrets were co-housed immediately after treatment. Weights and temperatures of all animals were monitored daily. Daily nasal wash samples (1 mL PBS) were collected from 1 DPI to 3 DPI for donor animals and from 1 day post-exposure (DPE) to 10 DPE for recipient animals. Donors were euthanized 3 DPI (2 DPE) and blood was collected by cardiac puncture from BXA- and placebo-treated ferrets. Recipients were euthanized 10 DPE.

[0141] Experiment 2 Antiviral treatment was initiated 1 DPI and co-housing of recipients was extended until 24 hours post-treatment (2 DPI). Weights and temperatures of all animals were monitored daily. Daily nasal wash samples (1 mL PBS) were collected from 1 DPI to 4 DPI for donor animals and from 1 DPE to 10 DPE for recipient animals. Donors were euthanized 4 DPI (2 DPE) and blood was collected by cardiac puncture from BXA- and placebo-treated ferrets. Recipients were housed until 16 DPE, at which point blood was collected by cardiac puncture.

[0142] Experiment 3Antiviral treatment was initiated 2 DPI and recipients were co-housed immediately thereafter. Weights and temperatures of all animals were monitored daily. Daily nasal wash samples (1 mL PBS) were collected from 1 DPI to 4 DPI for donor animals and from 1 DPE to 10 DPE for recipient animals. Donors were euthanized 4 DPI (2 DPE) and blood was collected by cardiac puncture from BXA- and placebo-treated ferrets. Recipients were housed until 16 DPE, at which point blood was collected by cardiac puncture.

[0143] Results and Discussion In three independent experiments, a single BXA treatment of ferrets infected with H1N1pdm09 significantly reduced infectious virus titers in the URT compared to placebo and oseltamivir (Figure 14). Mean virus titers in the baloxavir group were significantly reduced compared to the placebo group 24 hours after treatment in all experimental conditions (p ≤ 0.05). High infectious titers were maintained at donor endpoints in oseltamivir and placebo groups, whereas baloxavir-treated donors had a TCID 50 There were no positives (i.e., 0 / 4). The efficacy of baloxavir is superior to oseltamivir in treated donors (Figure 15). All (i.e., 4 / 4) oseltamivir-treated donors achieved TCID 50 The results were positive - none (i.e. 4 / 4) were reduced compared to placebo-treated donors.

[0144] In the ferret model used, recipients in the placebo group demonstrated a 100% frequency of contact infection with A / Perth / 265 / 2009 in naive ferrets (Figures 14-15). Recipients in the placebo group were 100% TCID 50The results show robust viral kinetics as measured by both RT-PCR and qRT-PCR, and high titer (>1280) serum antibody responses at the recipient endpoint (Figures 7, 10, 13). We observed that oseltamivir treatment did not reduce contact infection in naive ferrets. 100% of oseltamivir recipients showed infection parameters very similar to placebo, regardless of the timing of antiviral treatment (Figures 7, 10, 13). In contrast, baloxavir treatment within 24 hours of infection resulted in a 75% reduction in infection. In both experiments 1 and 2, only 1 / 4 recipients in the baloxavir group showed infection similar to placebo at TCID 50 Viral kinetic curves were shown (Figures 7, 10). Even when baloxavir treatment was performed 48 hours after infection, a 50% reduction in infection was observed (Figure 13).

[0145] The presence of high levels of viral RNA in the URT of baloxavir-treated ferrets did not correlate with changes in infectious virus titers measured by cell culture.

[0146] Although viral RNA was detected in 2 / 4 of baloxavir recipients in experiment 1, the copy numbers were approaching the threshold for positive detection, and the viral kinetics did not resemble the viral curves in the placebo group (Figure 7).

[0147] Despite the presence of viral shedding in the URT detected by qRT-PCR, these viruses appear unable to cause detectable infection in cell culture.

[0148] TCID in experiment 2 (Figure 10, 15563) and experiment 3 (Figure 13, 96642, 14779) 50 Antibody responses were detected in recipients of the negative baloxavir group, but titers were reduced 16- to 32-fold compared with recipients in the placebo group.

[0149] The mean plasma concentration of baloxavir reached a maximum (26.1 ng / mL) 3 hours after dosing and then gradually decreased toward the last sampling point (168 hours after dosing, 9.08 ng / mL). The results indicate that a single subcutaneous dose of 4 mg / kg (4 sites, 1 mg / kg per site) of baloxavir suspension can sustain baloxavir plasma concentrations for more than 1 week in ferrets.

[0150] Furthermore, the data clearly show that baloxavir treatment reduces contact transmission.

[0151] Example 3: Influenza transmission modeling with baloxavir Based on the surprising discovery that baloxavir marboxil can prevent influenza virus transmission, a simulation can be performed to show the effect of baloxavir treatment on influenza spread, which also considered the effect of baloxavir on the time to cessation of viral shedding (Tshed) observed in a Phase 3 clinical trial (NCT02954354). The simulation is -Influenza / social characteristics -Effects of various treatments This is done by predicting the percentage of patients infected during influenza epidemics and influenza pandemics by developing specific models consisting of:

[0152] About the Model Examples 1 and 2 above show that baloxavir treatment not only reduces viral shedding, but also, surprisingly, reduces transmission. The surprising and unexpected information that baloxavir marboxil can be used to reduce transmission is the prerequisite for the simulations carried out below, which simulate the effect of baloxavir marboxil treatment in the context of a (new) influenza epidemic or influenza pandemic.

[0153] The simulation uses an epidemiological SEIR model. First described in the early 20th century (Kermack and McKendrick), this model characterizes the number of infected people in a population by integrating different types of individuals: susceptible, exposed, infected, and recovered. Such models have been widely used in practice for planning against influenza pandemics, policy decisions regarding the stockpiling and development of antiviral drugs, and other interventions, and are described, for example, in Murillo, J Theor Biol. 2013. 332:267-290.

[0154] Assumptions 1) Viral shedding correlates with infectivity, with consistent infectivity during the period of viral shedding. 2) Phase 3 results will provide accurate estimates of elimination times for baloxavir and oseltamivir treatment. 3) All patients: -Same incubation period - Same disease duration -Same infection rate over the course of the disease - No specific interventions other than the procedure -No effect of age, geography or health on susceptibility Let us assume that.

[0155] Results and Discussion In both seasonal (see Figure 15) and pandemic (see Figure 16) scenarios, the proportion of infected patients was significantly reduced when treated with baloxavir compared to placebo or oseltamivir. The results indicate that the percentage of treated patients needed to cut the number of infected patients in half is approximately 15% for epidemics and 30% for pandemics, respectively. The exact thresholds for classifying an influenza outbreak as an "epidemic" or "pandemic" change from year to year. However, the results obtained suggest that treating at least 15% or at least 30% of infected individuals with baloxavir marboxil would likely prevent an influenza epidemic or influenza pandemic, respectively.

[0156] Example 4: Sequence-based epidemic identification Phylogenetic analyses (whole genome trees with tree topology or bootstrap support for clustering) and / or measures of genetic distance between paired populations (e.g., L1-Norm) can be performed to identify transmission pairs. Two factors influence the outcome of the analysis. First, the amount of sequence data available. To maximize this whole genome, next generation sequencing (WGNGS) can be performed to increase granularity and discriminatory power (compared to Sanger sequencing and / or single gene sequencing). Second, the diversity of the sampled community / metapopulation, allowing a high degree of confidence in assessing that viruses within a household pair are more similar to each other compared to the outgroup. More sequences obtained from the community will increase the diversity of this group, making it easier to identify real transmission pairs. Since sequencing of people not enrolled in the trial cannot be performed, we perform this analysis on subgroups of patients, focusing on sites of unique sequences where a suitable number of index cases (IPs) have been enrolled. Additionally, the inventors will attempt to obtain sequences from community databases from the same season (although this route is expected to be less successful).

[0157] In a previous study investigating influenza virus evolution in a HIVE cohort, 47 transmission pairs were analyzed and could be distinguished based on sequences. Thirty-four of those pairs were from one season (H3N2, 2014 / 2015). Based on these results, it is expected that 15 or more index patients (IPs), preferably at least 30-40 IPs, are sufficient to create a community distribution of pairwise distances reflecting the diversity of the community, and true transmission events (e.g., household transmission events) can be inferred as described in McCrone, John T., et al. "Stochastic processes constrain the within and between host evolution of influenza virus." Elife 7 (2018):e35962. As a method described for sequencing, the method described in McCrone (Elife 7 (2018):e35962) can be used. In the context of the present invention, the analysis is preferably focused on the analysis of influenza A virus samples. To better understand the method we used to identify transmission pairs and the considerations behind this method, we briefly review the contents of this paper by McCrone (Elife 7 (2018): e35962) below. McCrone (Elife 7 (2018): e35962) used both epidemiological linkage and genetic relatedness of the virus within households to define transmission pairs and eliminate confounding from community background diversity. More specifically, in McCrone (Elife 7(2018):e35962), studies of influenza A virus (IAV) populations in animal and human systems are described as finding that most intrahost single nucleotide polymorphisms (iSNVs) are rare, suggesting that intrahost populations are subject to strong purifying selection. In McCrone (Elife 7(2018):e35962), next-generation sequencing of intrahost influenza virus populations was used to define the evolutionary dynamics of IAVs within and between human hosts. A benchmark analysis pipeline was applied to identify iSNVs and characterize the genetic diversity of H3N2 and H1N1 populations collected over five post-pandemic seasons from individuals enrolled in a prospective household study of influenza. In McCrone (Elife 7(2018):e35962), the authors found that intrahost populations are dynamic and constrained by genetic drift and purifying selection. In a study by McCrone (Elife 7(2018):e35962), positive selection amplified rare beneficial de novo variants to frequencies above 2%. Contrary to what has been previously reported for human influenza transmission, but consistent with what has been observed for many other viruses with alternative modes of transmission, McCrone (Elife 7(2018):e35962) identified a very tight effective transmission bottleneck that limits the transmission of low-frequency variants.

[0158] In McCrone (Elife 7(2018):e35962), individuals within a household were considered epidemiologically linked transmission pairs if they tested positive for influenza virus of the same subtype within 7 days of each other. Some households had 3 or 4 symptomatic cases within this 1-week period, suggesting there was a longer chain of transmission.

[0159] In McCrone (Elife 7(2018):e35962) 2014), intrahost single nucleotide polymorphisms (iSNVs) were identified using an empirically validated analytical pipeline. Consistent with previous studies of natural infections and others, the authors of McCrone (Elife 7(2018):e35962) found that intrahost diversity in seasonal influenza A virus (IAV) populations was low. 243 of 249 samples had fewer than 10 minority iSNVs (median 2, IQR 1-3). The number of minority iSNVs identified was not affected by date of infection, viral load, subtype, or vaccination status.

[0160] In McCrone (Elife 7(2018):e35962), single nucleotide polymorphisms were evenly distributed across the genome. Minor variants were rarely shared by multiple individuals. 98% of minor iSNVs were detected only once, 2.3% were detected in two individuals, and no minor iSNVs were detected in more than two individuals. The low level of shared diversity suggests that populations within the host are exploring distinct regions of sequence space with little evidence of parallel evolution. The ratio of nonsynonymous to synonymous variants was 0.75, and given the excess of nonsynonymous sites across the genome and within the HA gene, these data suggest significant purifying selection within the host.

[0161] In McCrone (Elife 7(2018):e35962), the majority (68%) of iSNVs found in separate samples were either new or had previously been below the 2% detection limit. Collectively, the data in McCrone (Elife 7(2018):e35962) suggest that the populations present in the upper respiratory tract are highly dynamic while maintaining a stable consensus, that positive selection of novel variants within the host is inefficient, and that newly arising variants rarely amplify to frequencies above 2%.

[0162] Within-host data from McCrone (Elife 7(2018):e35962) suggest that newly emerged iSNVs with positive fitness effects are likely present at low frequencies (<2%) during acute infection. Maintenance of these mutations in host populations is therefore highly dependent on a transmission bottleneck.

[0163] In McCrone (Elife 7(2018):e35962), all individuals in a household who developed symptoms within 7 days were considered epidemiologically linked. The earlier onset individual of each putative pair was defined as the donor. Multiple possible donors who developed symptoms on the same day were ignored as transmission events. A donor and recipient could not develop symptoms on the same day unless both were the index cases in the household. Based on these criteria, the McCrone (Elife 7(2018):e35962) cohort had 124 putative household transmission events over five seasons. Of these, 52 pairs had samples of sufficient quality to reliably identify iSNVs from both individuals.

[0164] McCrone (Elife 7(2018):e35962) then used sequence data to determine which of these 52 epidemiologically linked pairs represented true household transmission events, as opposed to simultaneous community transmission. Genetic distances between influenza clusters from each household pair were measured by the L1 norm, and these distances were compared to those of randomly assigned community pairs for each season.

[0165] In McCrone (Elife 7(2018):e35962), only individuals in a randomly assigned pair were considered to be true transmission pairs if they had a genetic distance less than the 5th percentile of the community distribution of the pair. Forty-seven household transmission events met this criterion. Of these 47 validated household transmission pairs, three had no iSNVs in the donor and one further donor appeared to be mixedly infected. These four transmission events were removed from the bottleneck analysis because donors without iSNVs are not informative and mixed infection violates the model's assumption of site independence. Transmission bottlenecks were estimated for the remaining 43 high-quality pairs (37 H3N2, 6 H1N1).

[0166] A transmission bottleneck limits the amount of genetic diversity shared by both members of a pair. McCrone (Elife 7(2018):e35962) found that few minority iSNVs were polymorphic in both donor and recipient populations. Minority iSNVs in the donor were either absent or fixed in the recipient. The lack of common polymorphic sites suggests a strict effective bottleneck where only one allele can pass from donor to recipient.

[0167] The authors of McCrone (Elife 7(2018):e35962) conclude that acute influenza infections are characterized by low diversity, limited positive selection, and a severe bottleneck in transmission. Because viruses collected over five influenza seasons from individuals enrolled in a prospective household cohort were used, these dynamics are likely to be broadly representative of many seasonal influenza infections in temperate regions. The data in McCrone (Elife 7(2018):e35962) suggest that such rare variants are unlikely to transmit, even if selection falls below the level of detection. Given the estimated size of the bottleneck, the probability of transmission is approximately 1.7% for a variant with a frequency of 1% and approximately 3.3% for a variant with a frequency of 2%.

[0168] Example 5: Pharmacokinetic analysis in ferrets Materials, methods and results of animal experiments Outbred female ferrets, 28 months of age and weighing 650–802 g, were obtained from Japan SLC, Inc. They were identified by labeling the front of each cage with a sequential number. Animals were monitored at least once daily for clinical observations and were fed pelleted food (LabDiet High-Density Ferret Diet, Lab Supply, USA) and water ad libitum. End-point ferrets were euthanized by exsanguination under anesthesia with inhalation of isoflurane (Pfizer). Ferret studies were conducted at the Shionogi Pharmaceutical Research Center in accordance with animal experimental protocols approved by the Institutional Animal Care and Use Committee of Shionogi Co., Ltd. (Osaka, Japan).

[0169] Drug administration and blood sampling Active baloxavir acid (S-033447, hereafter BXA) was provided by the test material manager at Shionogi & Co., Ltd. The vehicle for BXA delivery was a 0.5 w / v% aqueous solution of methylcellulose (Fujifilm Wako, Japan) prepared in sterile water (hereafter MC solution). Using a mortar and pestle, BXA was suspended in the MC solution (1 mg / mL) and administered in a single treatment by subcutaneous injection four times at four sites in the dorsal region of reversibly anesthetized animals (total dose 4 mg / kg animal). After administration, to collect blood, bleeding was performed from the hindlimb vein by puncture, and blood (approximately 60–100 μL) samples were collected from the bleeding site at the scheduled time using a heparinized capillary tube (Drummond Scientific Company, USA). Plasma was obtained by centrifugation. Plasma samples were stored in a freezer at approximately −80°C until used for analysis by liquid chromatography with tandem mass spectrometry (LC-MS / MS) system.

[0170] Measurement of BXA in plasma Plasma concentrations of BXA were measured by LC-MS / MS consisting of an LC-20A system (Shimadzu, Japan) and an API 5000 (AB SCIEX, USA). Plasma samples were prepared by protein precipitation. Chromatographic separation was performed at 40 °C using an L-column 2 ODS metal-free (3 μm, 2.0 mm id × 50 mm, Chemicals Evaluation Laboratory, Japan). The binary mobile phase (0.1% formic acid in water and 0.1% formic acid in acetonitrile) was delivered in gradient mode at a total flow rate of 0.6 mL / min. The mass spectrometer was operated in electrospray ionization (ESI) positive mode with multiple reaction monitoring (MRM). Precursor / product transitions (m / z) of 484 / 247 and 490 / 247 were analyzed for BXA and the internal standard BXA-racemic-d4. 18 The concentrations of BXA and O were monitored and calculated based on the peak area ratios of BXA and the internal standard. The method was validated for selectivity, recovery, accuracy, precision, and stability under various conditions over a calibration range of 0.5–500 ng / mL.

[0171] Pharmacokinetic analysis The plasma concentration of BXA in each ferret was calculated using Analyst software (AB SCIEX, USA), and the mean and standard deviation were calculated using individual data using Microsoft Excel (Microsoft Co., USA).

[0172] Results and discussion The mean plasma concentration reached a maximum (26.1 ng / mL) 3 hours after administration and then gradually declined toward the last sampling point (168 hours after administration, 9.08 ng / mL). The results indicate that a single subcutaneous dose of BXA suspension at 4 mg / kg (4 sites, 1 mg / kg per site) can maintain plasma concentrations of BXA in ferrets for more than 1 week.

[0173] The present invention refers to the following nucleotide and amino acid sequences: SEQ ID NO: 1: Forward primer for real-time PCR 5' GACCRATCCTGTCACCTCTGA 3' SEQ ID NO:2: Reverse primer for real-time PCR 5' AGGGCATTYTGGACAAAKCGTCTA 3' SEQ ID NO: 3: Probe for real-time PCR ("FAM" means fluorescein amidite, i.e., a fluorescent dye for oligonucleotides. "BHQ1" means black hole quencher 1, i.e., a quencher. BHQ1 and FAM together are not fluorescent. After the probe is cleaved, FAM becomes fluorescent) 5' FAM-TCGAGTCCTCGCTCACTGGGCACG-BHQ1 3'

[0174] SEQ ID NO: 4: Influenza A virus (A / WSN / 1933 (H1N1)): GenBank: X17336.1 (including the I38T mutation). The I38T mutation is underlined and shown in bold. MEDFVRQCFNPPMIVELAEKAMKEYGEDLKIETNKFAA TCTHLEVCFMYSDFHFIDEQGESIVVELGDPNALLKHRFEIIEGRDRTIAAWTVINSICNTTGAEKPKFLPDLYDYKKNRFIEIGVTRREVHIYYLEKANKIKSEKTHIHIFSFTGEEMATKADYTLDEESRARIKTRLFTIRQEMASRGLWDSFRQSERGEETIEERFEI TGTMRKLADQSLPPNFSSLENFRAYVDGFEPNGYIEGKLSQMSKEVNARIEPFLKSTPRPLRLPDGPPCSQRSKFLLMDALKLSIEDPSHEGIPLYDAIKCMRTFFGWKEPNVVKPHEKGINPNYLLSWKQVLAELQDIENEEKIPRTKNMKKTSQLKWALGENMAPE KVDFDDCKDVGDLKQYDSDEPELRSLASWIQNEFNKACELTDSSWIELDEIGEDAAPIEHIASMRNYFTAEVSHCRATEYIMKGVYINTALLNASCAAMDDFQLIPMISKCRTKEGRRKTNLYGFIIKGRSHLRNDTDVVNFVSMEFSLTDPRLEPHKWEKYCVLEVG DMLLRSAIGHVSRPMFLYVRTNGTSKIKMKWGMEMRRCLLQSLQQIESMIEAESSVKEKDMTKEFFENKSETWPVGESPKGVEEGSIGKVCRTLLAKSVFNSLYASPQLEGFSAESRKLLLIVQALRDNLEPGTFDLGGLYEAIEECLINDPWVLLNASWFNSFLTHALR SEQ ID NO: 5: Sequence fraction of influenza A virus (A / WSN / 1933 (H1N1)): GenBank: X17336.1 (including the I38T mutation). The I38T mutation is underlined and shown in bold. F.A.A. T CTH

Claims

1. Formula (I) or (II): 【Chemistry 1】 or a pharma- ceutical composition for preventing the transmission of influenza virus from a patient (index patient) infected with influenza virus to a contact by administering the pharmaceutical composition to the patient.

2. The pharmaceutical composition of claim 1, which reduces the infectivity of influenza virus in a newly diagnosed patient.

3. 3. The pharmaceutical composition of claim 1 or 2, wherein the rate of transmission of influenza virus from an index patient is reduced within 1 to 32 hours after the first administration of the compound.

4. 4. The pharmaceutical composition of any one of claims 1 to 3, wherein the rate of transmission of influenza virus from an index patient is reduced within 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, 30 hours, or 32 hours of the first administration of the compound.

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the transmission rate of influenza virus from treated index patients is reduced by no more than 70%, preferably no more than 50%, more preferably no more than 30% compared to the transmission rate of influenza virus from control patients.

6. The method of claim 5, wherein a control patient is infected with influenza virus and is not administered the compound.

7. The pharmaceutical composition according to claim 5 or 6, wherein the control patient is administered an anti-influenza drug other than a compound of formula (I) or (II) or a pharma- ceutically acceptable salt thereof.

8. The pharmaceutical composition according to any one of claims 5 to 7, wherein the control patient is not administered an anti-influenza drug.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein transmission occurs when at least one contact of the treated index patient or the control patient becomes infected with influenza virus after personal contact with the treated index patient or with a control patient, respectively.

10. 10. The pharmaceutical composition of claim 9, wherein a contact of the treated index patient is: (i) the index patient was not infected with influenza virus at the time the compound was first administered to the index patient; and (ii) had personal contact with the treated index patient during the index patient's influenza virus infection period.

11. 11. The pharmaceutical composition of claim 10, wherein the contact has had personal contact with the treated index patient within 10 days of administration of the compound to the index patient.

12. The pharmaceutical composition according to claim 10 or 11, wherein the contact has had personal contact with the treated index patient within the period starting from administration of the compound and ending 5 to 10 days after administration.

13. The pharmaceutical composition according to any one of claims 9 to 12, wherein the contacts of a control patient are: (i) was not infected with influenza virus at the time the influenza anti-influenza drug was first administered to the control patient or at the corresponding time point considering the influenza disease process if the influenza anti-influenza drug was not administered to the control patient; and (ii) had personal contact with the control patient during the control patient's period of influenza virus infection;

14. The pharmaceutical composition of claim 13, wherein the contact has had personal contact with the control patient within 10 days of administration of the anti-influenza drug to the control patient, or within a corresponding period of time that would take into account the influenza disease process if the anti-influenza drug had not been administered to the control patient.

15. The pharmaceutical composition according to claim 13 or 14, wherein the contact has had personal contact with the control patient within a period beginning with administration of the anti-influenza drug to the control patient and ending 5 to 10 days after administration, or within a corresponding period taking into account the influenza disease process if the anti-influenza drug was not administered to the control patient.

16. 14. The pharmaceutical composition of claim 10 or 13, wherein the contact is PCR negative for influenza at the time defined in (i).

17. The pharmaceutical composition according to any one of claims 9 to 16, wherein said personal contact is contact capable of airborne and / or direct contact transmission, preferably only airborne transmission.

18. The pharmaceutical composition according to any one of claims 9 to 17, wherein transmission from the treated index patient has occurred if influenza virus is detectable in at least one contact of the treated index patient.

19. 20. The pharmaceutical composition of claim 18, wherein transmission from the treated index patient has occurred if influenza virus is detectable in at least one contact of the treated index patient within 15 days of administration of the compound.

20. The pharmaceutical composition according to any one of claims 9 to 19, wherein transmission from a control patient has occurred if influenza virus is detectable in at least one contact of the control patient.

21. The pharmaceutical composition of claim 20, wherein transmission from a control patient has occurred if influenza virus is detectable in at least one contact of the control patient within 15 days of administration of another anti-influenza drug to the control patient, or within a corresponding period taking into account the influenza disease process if an anti-influenza drug had not been administered to the control patient.

22. The pharmaceutical composition according to any one of claims 3 to 21, wherein the transmission rate is measured by testing at least one contact of the treated index patient or the control patient, respectively, for influenza virus infection within 10 days of administration of the compound to the treated index patient, or within 10 days of administration of another anti-influenza drug to the control patient, or within 10 days of the corresponding time point taking into account the influenza disease process if no anti-influenza drug was administered to the control patient.

23. The pharmaceutical composition of any one of claims 1 to 22, wherein influenza virus infection is present when influenza virus can be detected.

24. 24. The pharmaceutical composition of claim 23, wherein the influenza virus is detected via PCR.

25. 24. The pharmaceutical composition of claim 23, wherein the influenza virus is detected by using an influenza test kit.

26. Transmission from the index patient has occurred if at least one contact of the index patient has influenza virus infection with an influenza virus strain identical to that of the index patient; Transmission from a control patient has occurred if at least one contact of the control patient has influenza virus infection with an influenza virus strain identical to that of the control patient. A pharmaceutical composition according to any one of claims 1 to 25.

27. The pharmaceutical composition according to any one of claims 1 to 26, wherein the influenza virus is transmitted by direct contact and / or airborne transmission.

28. The pharmaceutical composition according to any one of claims 1 to 27, wherein after administration of the compound and during influenza virus infection, the treated index patient is in personal contact with at least one person in an influenza risk group or at least one person essential for the functioning of society.

29. 30. The pharmaceutical composition of claim 28, wherein at least one person in the influenza risk group is at least one person at high risk of being infected with influenza virus or developing influenza-related complications.

30. 30. The pharmaceutical composition of claim 29, wherein the influenza-related complication is at least one complication selected from the group consisting of hospitalization, sinusitis, otitis media, bronchitis and pneumonia.

31. 31. The pharmaceutical composition of claim 29 or 30, wherein at least one person at high risk of developing influenza-related complications is at high risk of dying due to influenza virus infection.

32. The pharmaceutical composition according to any one of claims 29 to 31, wherein at least one person at high risk of developing influenza-related complications is a person who: (i) suffers from chronic cardiovascular disease, chronic pulmonary disease, chronic metabolic disease, chronic renal disease, cardiopulmonary disorder, and / or immunodeficiency; and / or (ii) Being 65 years of age or older, or being under 5 years of age.

33. The pharmaceutical composition according to any one of claims 29 to 32, wherein at least one person at high risk of infection with influenza virus is a person for whom influenza vaccination is contraindicated.

34. 34. The pharmaceutical composition of any one of claims 28 to 33, wherein at least one person essential to the functioning of society works as an essential service provider, including firefighters, police personnel, medical personnel, emergency response service personnel, the military or government.

35. The pharmaceutical composition according to any one of claims 1 to 34, wherein the treated index patient has personal contact with many people during influenza virus infection after administration of the compound.

36. After administration of the compound and during influenza virus infection, the treated index patient: (i) visiting a care facility, educational facility, public institution, transport facility, vehicle, aircraft and / or shop; (ii) Have personal contact with many people A pharmaceutical composition according to any one of claims 1 to 35.

37. 37. The pharmaceutical composition of claim 35 or 36, wherein the compound is administered at least 1 hour prior to said personal contact.

38. 38. The pharmaceutical composition of any one of claims 35 to 37, wherein the compound is administered at least 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, 30 hours or 32 hours prior to said personal contact.

39. The pharmaceutical composition of any one of claims 1 to 38, wherein the compound is administered within 48 hours of the onset of influenza symptoms.

40. The pharmaceutical composition of any one of claims 1 to 39, wherein the compound is administered once as a single treatment.

41. The pharmaceutical composition of any one of claims 1 to 40, wherein the effective amount is about 40 mg for a patient weighing less than 80 kg and about 80 mg for a patient weighing 80 kg or more.

42. The pharmaceutical composition of any one of claims 1 to 41, wherein the compound is administered orally.

43. The pharmaceutical composition according to any one of claims 1 to 42, wherein the index patient is at least 12 years old.

44. The pharmaceutical composition of any one of claims 1 to 43, wherein treated index cases patients have a reduced risk of causing an influenza epidemic or influenza pandemic compared to control patients.

45. The pharmaceutical composition according to any one of claims 1 to 44, wherein the influenza virus is an influenza A virus or an influenza B virus.

46. The pharmaceutical composition according to any one of claims 1 to 45, wherein the influenza virus is an epidemic or pandemic influenza virus strain.

47. 47. The pharmaceutical composition of any one of claims 1 to 46, wherein the influenza virus is antigenically different compared to the parent influenza virus strain as a result of antigenic drift and / or antigenic shift.

48. The pharmaceutical composition according to any one of claims 1 to 47, wherein the influenza strain is a recycled virus that has previously caused an epidemic or pandemic.

49. The pharmaceutical composition according to any one of claims 1 to 48, wherein the influenza virus strain does not have an I38X mutation but has an I38T mutation.

Citation Information

Patent Citations

  • Compositions and methods for reducing transmission of disease

    JP2008523153A